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ABSTRACT
Valvular heart diseases lead to over 290,000 heart valve replacements worldwide
each year, and approximately half of these involve replacement with a bioprosthetic heart
valve (BHV) [43].

BHVs exhibit excellent hemocompatibility, but suffer from

inadequate long-term durability with most adult implanted valves failing within 12 to 15
years after implantation [62]. Although this may be adequate for some individuals, BHV
implantation may be contraindicated in younger individuals to avoid reoperation. Even
in elder recipients, valve dysfunction can still cause death or reoperation that could be
avoided with increased BHV durability.

Therefore, investigation into methods of

increasing BHV durability can not only improve the quality of life for BHV recipients,
but widen the accessible patient demographic as well.
All BHVs are currently treated with glutaraldehyde, which is used to stabilize
collagen through crosslinking as well as reduce tissue immunogenicity.

However,

glutaraldehyde crosslinking potentiates BHV calcification and also causes undesirable
alterations to tissue properties that are conducive to structural degeneration [5,78,143].
Considering that calcification and structural degradation are the foremost causes of BHV
failure, there has been interest in alternative, non-glutaraldehyde fixation methods [5].
One phenomenon that can contribute to structural degeneration is the loss of
glycosaminoglycans (GAGs) from cuspal tissue [15,19].

GAGs are large highly

hydrophilic molecules that form a gel-like sheet within the center layer of valve cusps.
This layer aids in stress absorption and reduction of shearing between the other tissue
layers [18]. GAGs lack the amine functionalities to be crosslinked by glutaraldehyde and
under current fixation methods are lost during preparation, in vivo implantation and
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storage [18,19,75]. Carbodiimide crosslinking with EDC and NHS reacts with available
carboxyl groups in addition to amine groups allowing for the crosslinking of both GAGs
and collagen. These crosslinks may aid in GAG preservation and thereby contribute to
improved mechanical function. However, it has been shown that crosslinking alone is
not sufficient to fully preserve GAGs, as they are still prone to loss through enzymatic
degradation [132].
Neomycin, a hyaluronidase inhibitor, has been shown previously to prevent the
enzymatic degradation of GAGs [133]. Neomycin also contains amine functionalities
that enable stable incorporation into carbodiimide-initiated crosslinks.

This study

investigates the effects of carbodiimide crosslinking in combination with neomycin on
the stability of structural proteins, GAG preservation, calcification, and biomechanical
properties.
The incorporation of neomycin into EDC, and NHS fixation (NEN) was found to
improve GAG retention, fully preventing loss during storage, implantation, and direct
enzymatic digestion.

Additionally, the use of neomycin enhanced the elastin and

collagen stability of EDC and NHS crosslinking alone (EDC).

When compared to

glutaraldehyde crosslinked tissues (GLUT), NEN treated tissues demonstrated
comparable collagen and elastin stability but far superior GAG retention. EDC and NEN
groups also displayed reduced stiffness and increased extensibility when compared to
GLUT crosslinked tissues. These results suggest that NEN fixation and resulting GAG
preservation may improve the mechanics of BHV tissues. In doing so, tissue stress and
loads that occur during function may be reduced, preventing the onset of collagen
damage and increasing the lifespan of BHVs.
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1.

LITERATURE REVIEW
1.1.

Anatomy of the Heart

The human heart is a physiological pump that ensures continuous transport of
blood throughout the body for the entire lifetime of an individual. It contains four
distinct chambers consisting of two ventricles and two atria, both left and right. The right
chambers of the heart contribute to the body’s pulmonary circulation while the left side of
the heart provides systemic circulation. Blood is driven through the body by pressure
gradients that have varying intensities in different sections of the heart [1-3]. Due to the
much greater resistance offered by systemic circulation, mean pressures are higher in the
left side of the heart where average values are approximately 80 mm Hg during diastole
and 120 mm Hg in systole upon entry into the aorta. Pressures in the right side are much
milder amounting only to values of around 10 - 25 mm Hg in the pulmonary artery [1,2].
Blood transport in the heart begins at the right atrium. Deoxygenated blood is
received from the inferior and superior vena cava before passing blood into the right
ventricle for delivery to the lungs using the pulmonary arteries. Oxygenated blood from
the lungs is then transported to the left atrium through the pulmonary veins and lastly into
the left ventricle, which distributes blood to the rest of the body via the aorta. The heart
itself is supplied with blood by the coronary arteries that originate in the left and right
aortic sinus at the aortic root. Deoxygenated blood from the heart collects in the coronary
sinus and empties into the right atrium to again to be cycled through the heart [1-3].
In order to ensure efficient and constant forward blood motion throughout the
heart, there are four valves in place that function to prevent backflow. These valves are
composed of connective tissue formed into “cusps” or “leaflets” that open and close to
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regulate blood flow [1-3]. These valves are located at the entrance and exit of each
ventricle and are each attached at their base to the cardiac skeleton. The cardiac skeleton
separates the atria from the ventricles and although it is not a true skeleton, is composed
of dense connective tissue and provides vital structural support to the heart. The fibrous
rings that compose the cardiac skeleton serve as attachment points for the heart valves,
muscular fibers, and major vessels in the heart. The attachment point for the heart valve
cusps on the cardiac skeleton is known as the annulus, which is an important reference
point when concerning native and artificial heart valve position [2].
Two of the four valves located in the heart are known as the atrioventricular (AV)
valves, while the other two are identified as the semilunar valves [1-3]. Under normal
circumstances, these valves function constantly throughout the approximately 3 billion
cardiac cycles that occur in a single lifetime [4]. The AV valves separate each of the atria
from their respective ventricles and prevent backflow from the ventricles during systole.
The right AV valve is commonly known as the tricuspid valve, while the left is called the
mitral valve [1-3]. These valves are anchored to the heart wall by thread-like structures
called chordae tendineae. These collagen-based structures are attached to the heart wall
at the papillary muscles, which contract during systole in order to pull the chordae
tendineae taut and prevent over closure and inversion of the AV valves [1-2]. The
closure of these valves is associated with the first heart sound, coined “lubb”, while the
second heart sound results from closure of the two remaining heart valves after
ventricular systole and is termed “dubb”. These other two valves, the semilunar valves,
are named the pulmonary and aortic valves. They lead into the pulmonary arteries and
aorta respectively and prevent retrograde flow into the ventricles [1-3].
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Figure 1. Cross-section of Heart and Blood Circulation Diagram (Adapted from [2]).

1.1.1. Heart Valves
Heart valves are composed of cusps or leaflets that open and close to regulate
blood flow. Each valve in the heart has three cusps that seal together during closure
except for the mitral valve, which has only two. Although the basic function of heart
valves is simple, the role they fill is quite demanding. Despite being in the extremely
volatile environment of the bloodstream, each valve must exhibit nearly flawless function
through an astounding number of cycles. The valves face constant blood flow, sharp
pressure changes, and other environmental stresses that call for an extremely durable and
specialized structure. Discussion in this section will primarily concern the aortic heart
valve.

It is the most commonly diseased and replaced heart valve, with many

bioprosthetic heart valve replacements being constructed from xenogenic aortic valve
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tissue [5]. There are some morphological differences between the different heart valves
of the body, yet their primary compositions are comparable.

For our purposes,

knowledge of the aortic heart valve will suffice.
The aortic valve is located at base of the aorta and marks the exit of blood from
the heart into the body’s vasculature. The valve leaflets are an extension of the cardiac
endocardium and fibrous skeleton. The fibrous ring on which they are positioned is
known as the aortic annulus [5,6]. This is the main load bearing structure for the valve
and serves as the transfer point of stresses to the aortic wall [5,11]. Adjacent to each cusp
are round bulges in the aortic wall that are collectively called the aortic sinuses. These
structures prevent valve leaflets from sticking to the aortic wall during opening, and also
promote the formation of vortices in the blood flow that aid in valve closure [4,7]. Many
structures contribute to overall aortic valve function, but the cusps will be the main topic
since they are the primary structures of concern when discussing valve disease and
replacement [5].
Aortic valve cusps are thin and translucent structures composed of connective
tissue that is roughly semi-circular in shape. For the most part, they are avascular
structures.

They primarily support themselves by obtaining nutrients from the

bloodstream via diffusion [5].

Although the cusps are microscopically complex

structures, their surfaces contain very few noticeable macroscopic features. There exists
a free edge that provides coaptation during closure with up to 40% of cusp surface area
coming into contact with the other cusps [5]. The cusps are connected to the aortic
annulus on the opposite side. This attachment is continuous until terminating at the free
edge on both ends at the commissures. Besides these primary points of reference, one
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side of the cusp is noticeably smoother than the other. Also, in the center of the cusp
there is a thick nodular region, the Nodule of Arantius, where all three cusps meet in the
center during closure [8].

Despite their bland external appearance, the internal

composition of the aortic valve leaflet is much more interesting. It is a specialized blend
of various structures including valvular interstitial cells (VICs), valvular endothelial cells
(VECs), and large quantities of various extracellular matrix (ECM) components [5,6].

A

B

Figure 2. [A] Aortic valve cusp [4]. [B] Fibrous skeleton and valves of the heart [2].

1.1.1.1.
1.1.1.1.1.

Heart Valve Cell Types
Endothelial Cells

Endothelial cells (ECs) are a single layer of cells that are continuous throughout
the entire cardiovascular system. This layer of cells lines the lumen of all blood and
lymph vessels as well as other structures in the bloodstream filling many roles vital to
normal cardiovascular function [1,2,7,8]. ECs provide the ideal smooth, non-adherent
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surface that allows blood components to pass through the valve unimpeded and
undamaged. Additionally, through the release of certain biomolecules, ECs also promote
uninterrupted blood flow through the inhibition of thrombosis and maintenance of
hemostasis. Other factors secreted by ECs, as well as certain EC cell surface markers,
play essential roles in immune and inflammatory responses and contribute to
management of local blood flow through vasomotion control. The endothelial cell layer
also serves as a barrier between the lumen of the blood vessel and the exterior tissues. It
not only provides a physical obstruction, preventing the exposure of internal valve
components, but also controls the passage of nutrients, wastes, cells, and other materials
by both diffusion and bulk transport into the underlying tissues from the bloodstream
[1,8].

1.1.1.1.2.

Valvular Interstitial Cells

The other main cell type existing in heart valves is the valvular interstitial cell
(VIC). VICs have an elongated cell shape with narrow connecting projections that form
a network throughout the valvular matrix [26].

These cells, also known as

myofibroblasts, have the characteristics of both smooth muscle cells (SMCs) and
fibroblasts and are thought to be primarily responsible for maintaining extracellular
matrix homeostasis [6,26]. Similar to fibroblasts, VIC metabolic activities are highly
geared towards producing, degrading, and reorganizing large amounts of matrix
components [5,6]. However, their SMC-like properties enable them to display contractile
capabilities which may aid in the maintenance of suitable internal stress levels [26]. The
distinct contractile and metabolic characteristics of myofibroblasts allow them to
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uniquely respond to various stimuli. The specialized nature of VICs enables them to
respond to the constantly changing body environment and aid in the maintenance of the
balance necessary for heart valve cusps to perform their intense physiological duties [6].

1.1.1.2.

Extracellular Matrix

The majority of connective tissue volume is composed of extracellular matrix
[1,7]. Heart valve cusps are no exception and are formed from a mixture of collagen,
elastin and glycosaminoglycans [5,6]. Heart valve durability is strongly based upon the
condition of the matrix and its ability to remodel efficiently [11]. Each matrix molecule
has a specific structure and function within the valve, and when arranged accordingly,
these molecules provide the structural support and flexibility heart valve cusps.

1.1.1.2.1.

Collagen

Collagen is the main structural molecule within heart valve cusp tissue and is also
the most abundant protein. Collagen accounts for approximately 90% of heart valve cusp
protein and about 55% of the young adult human cusp by dry weight [9,10]. There are
multiple types of collagen present in cusp tissue, with the majority being type I collagen
(~70%) and the remainder being mostly type III (~25%) [9]. Collagen organizes itself
into larger fibrous formations, or aggregates, based upon a triple helix molecule subunit
of three linear amino acid chains wound together. The resulting long fibrous formations
enable collagen to exhibit very high tensile strength, but low resistance to torsional and
flexural stress. When properly aligned, this organized structure enables collagen to
provide most of the valve’s matrix strength and durability [13].
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1.1.1.2.2.

Elastin

Elastin is a branched and coiled protein with the ability to stretch when forces are
applied [2,7,10]. If the forces are removed, elastin returns to its original state allowing it
to impart flexibility onto the tissues it inhabits [10,13]. Elastin is rich in non-polar amino
acids, making it insoluble and giving it a hydrophobic nature [12]. Unlike collagen,
which can only withstand elongations of 1-2%, elastin can maintain strains of 150%
without fracture.

However, elastin may improve the elasticity of collagen through

interfiber connections. These connections also allow collagen to return to its natural state
when unloaded, giving aortic valve tissue great strength and extensibility. Elastin is the
second most abundant protein in aortic valve cusps and it accounts for 13% of the dry
weight in young adults [10].

1.1.1.2.3.

Glycosaminoglycans

Glycosaminoglycans (GAGs) are long unbranching polysaccharides composed
of repeating disaccharide units containing a hexosamine and a hexuronic acid, or
hexose [16]. These molecules are found in many places throughout the body,
including cartilage, tendons, vitreous humor, synovial fluid and aortic valve cusps.
There are five main species of GAGs including hyaluronic acid (HA), chondroitin
sulfate (CS), dermatan sulfate (DS), keratan sulfate, and heparin/heparin sulfate
(HS) [17]. Most GAGs are sulfated and can be covalently linked to core proteins in
order to form proteoglycans (PGs) [18, 19]. However, non‐sulfated HA does not
covalently bind, but instead can act as a core connecting with proteoglycans, such as
aggrecan, via link proteins resulting in large brush‐like structures [18‐23].
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All GAG species have been found in human heart valves, but those primarily
found are HA, CS, and DS, with significant amounts in PGs versican and decorin
[18,19,26]. Approximately 60% of the GAGs found in cusp tissue are HA with the
remainder being primarily CS (~30%) or constituents of the PG decorin (~10%)
[24, 26]. GAGs are highly anionic due to elevated concentrations of uronic acid and
sulfate groups making them very hydrophilic [24]. This allows them to absorb many
times their weight in water and, while only representing 3.5% of cusp dry weight,
this behavior allows GAGs to substantially affect valve properties, structure and
biomechanics [25]. GAGs play many roles in aortic valve structure and function.
This section includes only a brief overview of GAGs. For a more detailed discussion
please refer to section 1.2.

A

B

Figure 3. [A] Large PG structure, aggrecan bound to an HA core. (adapted from
[21]). [B] Disaccharide unit of the primary aortic valve GAGs (adapted from [17]).
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1.1.1.3.

Aortic Valve Layers

Heart valves exhibit three distinct layers that provide various structural and
functional purposes that contribute to normal valve function. These three layers, the
fibrosa, spongiosa, and ventricularis, differ both compositionally and morphologically
from one another making each specialized in serving its particular purpose. The fibrosa
is located on the superior aortic valve surface facing the aorta when the valve is closed.
The ventricularis is located opposite of the fibrosa and faces the left ventricle while the
intermediate spongiosa layer forms a barrier separating the other two layers [5,6,14,26].

Figure 4. [A] Depiction of aortic valve cusp section showing tri-layered structure
including basic cell and molecular composition [46].

1.1.1.3.1.

Fibrosa

The fibrosa faces the exit side of the aortic valve and is the primary load-bearing
tissue layer [5,6,10,26]. This layer is continuous with the cardiac skeleton and like the
fibrous ring is composed of high proportions of collagen [6].

The collagen is

predominantly aligned parallel to the free edge giving it highly aniosotropic properties
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[5]. Consequently, the aortic valve cusps are extremely yielding in the radial direction,
yet equally tough in the circumferential. The higher compliance in the radial direction
allows valves to open with relative ease in response to blood flow while the strength
imparted by the circumferentially aligned fibers makes the cusps stand firm when met by
backflow. Additionally, the rigidity associated with the aligned fibers keeps the cusps
taut, which helps promote coaptation and prevents regurgitation [5].
In order to provide support for the fibrosa’s high radial strains, corrugations are
present to help mitigate the formation of high stresses [5]. The corrugations of the fibrosa
facilitate large amounts of cusp expansion and contraction that occur during normal valve
function [26]. Furthermore, microscopic collagen waves are also present, which makes
the collagen fibers slightly more extensible and alleviate stresses in the circumferential
direction [5,10]. Together, the features of the fibrosa make this layer the load-bearing
workhorse of the aortic valve cusp.

A

B

Figure 5. [A] Radial cross-section of porcine aortic valve cusp showing tri-layered
structure and fibrosa corrugation [5]. [B] Circumferential cross-section of aortic valve.
View of microscopic collagen crimping [29].
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1.1.1.3.2.

Ventricularis

The ventricularis is the bottom layer of the aortic valve that faces the left ventricle
when the valve is closed [5,10,11,27]. This layer is the thinnest layer and is composed
primarily of dense collagen fibers, which are less orderly than those in the fibrosa [10].
The ventricularis is also smoother than the fibrosa and displays a significantly higher
elastin content through a large proportion of radially aligned elastin fibers [5,11].
The abundance of elastin fibers is thought to support the maintenance of
collagen fiber architecture as well as provide elastic recoil during valve function [10].
This recoil occurs because the ventricularis is naturally preloaded in tension making it
contract when in the relaxed state [28]. This occurs at the beginning of systole and helps
snap the valve open quickly. The preloaded state of the ventricularis also allows the
valve to exhibit beneficial changes in cusp surface area during opening and closing,
which helps maximize valve efficiency. Contraction during opening causes a reduction
in cusp surface area, which minimizes interference with blood flow while elastic
stretching during valve closure provides maximum coaptation [5,11].

Figure 6. Cross-section showing ventricularis and fibrosa changes from systole to
diastole. (adapted from [4]).
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1.1.1.3.3.

Spongiosa

The spongiosa is the central layer of the aortic valve cusp that consists of loosely
arranged collagen fibers and a plentiful quantity of glycosaminoglycan molecules and
proteoglycans [5,11]. The high GAG and PG content of the spongiosa gives it an
extremely high hydration capacity.

So, despite its lack of structural strength, the

spongiosa absorbs large amounts of water and takes on a gel-like structure with
substantial thickness that demonstrates considerable contribution to overall valve
function [5,18,29].
As mentioned above, the fibrosa and ventricularis undergo a large amount of
expansion, contraction and bending during normal valve function. The differences in the
deformations that occur between these two layers create large amounts of shear stress if
uninhibited.

The spongiosa acts as a flexible fluid barrier between the two main

structural layers that minimizes shear stresses by lowering friction. The lubrication
properties of the spongiosa allow for great mobility between the fibrosa and ventricularis.
Alleviation of these high shear stresses that occur during flexure can prevent acute valve
damage or even separation of the aortic valve layers [5,18,28,29].
The yielding nature of the spongiosa permits minimal interference with valve
motion while still providing necessary thickness to the cusp.

Its thickness ensures

isolation of both the fibrosa and ventricularis and helps prevent tissue buckling [18,31].
Tissue buckling occurs during bending of the valve at sites of high compressive stress;
however, GAGs and PGs express a viscoelastic response under compressive loading that
results in the spongiosa’s high resistance to compressive force and capability of efficient
shock absorption [5,18,19,30].
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1.2.

Glycosaminoglycans (GAGs) and Proteoglycans (PGs)
1.2.1. GAG and PG Structure

As mentioned previously in section 1.1.1.2.3, GAGs are long unbranching
polysaccharides composed of repeating disaccharide units containing a hexosamine and a
hexuronic acid or hexose [16]. These molecules are found in many places throughout the
body including cartilage, tendons, vitreous humor, synovial fluid, and heart valve cusps.
With the exception of hyaluronan, most GAGs are sulfated and can be covalently linked
to core proteins in order to form PGs [18, 19]. The presence of these sulfate groups, as
well as uronic acid residues, makes GAGs and their associated PGs highly anionic. This
elevated concentration of charges results in the expression of extreme hydrophilicity [24].
There are approximately 30 different PG varieties that differ based upon the
number, size, and type of the attached GAG chains as well as the structure of the protein
core and location [17]. According to these characteristics PGs are grouped into five
families. However, only two significantly associated with aortic valve cusps, hyalectins
and small leucine rich proteoglycans (SLRPs) [17,19]. Hyalectins are large PGs capable
of non-covalently associating with hyaluronan via link proteins and include aggrecan,
versican, brevican, and neurocan [17,22]. Common SLRPs include decorin and biglycan
which are small PGs consisting of one or two GAG chains attached to a protein core
containing areas rich in leucine repeats [17,19].
Chondroitin sulfate (CS) and hyaluronan (HA) represent the large majority of
GAGs present in aortic valve cusp tissue. Dermatan sulfate (DS) also has a significant
presence in smaller amounts and, together with CS and HA, account for 90% of all cusp
GAGs [19]. These GAGs are primarily found in the form of PGs as versican and decorin
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[19]. Versican, a large PG, is comprised of 12-15 CS chains that attach to their protein
core using available serine residues [17]. It is mostly found in the spongiosa layer
complexed with HA to form large brush-like structures. Decorin is the most frequently
found small PG in aortic valve cusp tissue, although biglycan is also found in smaller
amounts [19,131].

1.2.2. GAG and PG Function
The function of PGs is largely controlled by the characteristics of associated GAG
side chains. The high concentration of anionic charges on large PG aggregates is a result
of high CS expression and leads to the absorption and retention of large amounts of water
[21]. Not only does this play a role in tissue hydration, but also nutrition and solute
transport as well. These large, hydrated, brush-like structures take on a gel-like state that
simulates a porous system limiting the movement of water as well as various solutes and
nutrients [16]. The micro-flow of water within this networked gel structure, along with
intra/intermolecular electrostatic repulsions, yields a contribution to the viscoelastic
nature of cusp tissue [16,17,19,23,130].

These large PG structures have a large

involvement in valve biomechanics by rendering occupied tissues resistant to
compression, facilitating efficient load distribution, and enabling reversible deformation
under mechanical load [16,17,19]. In fact, the osmotic properties of aggrecan have been
established to provide greater than half of cartilage’s compressive modulus further
demonstrating the biomechanical importance of these molecules [22]. Additionally, these
structures can interact with collagen assemblies and have been stated to play a possible
role in binding specific enzymes or other biosignaling molecules [16].
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Small PGs are thought to be associated with the formation and organization of
other ECM components [17]. Specifically, they interact with collagen through their core
protein or side GAG chains and play a role in collagen fibrillogenesis [19]. SLRPs
decorin and biglycan of aortic valve cusps utilize their leucine rich domains to bind to
fibril-forming collagens. The full function of these is not known, but they are stated to
modify the rate of fibril formation as well as play a role in end-stage production or
termination [21]. Decorin and biglycan have also been suggested to aid in elastogenesis,
which is supported by the fact that their highest expression is found in the ventricularis
layer of cusp tissue [131].

1.3.

Native Heart Valve Disease

Proper heart valve function is necessary to maintain normal blood flow, thereby
ensuring the transport of vital nutrients throughout the body. Heart valve disease can
cause the valves to become dysfunctional, therefore disrupting normal blood flow. This
disruption can lead to many symptoms, including shortness of breath, fatigue, edema,
heart palpitations, chest pain, and even death. A valve is termed dysfunctional when it
cannot open properly (stenosis) or close fully (insufficient). Stenosis causes the valve to
become a blockage that impedes normal blood flow exiting the heart, while a valve
insufficiency is best described as a leaky valve that allows back flow or regurgitation
during diastole. Stenosis and insufficiency are not mutually exclusive and can occur
together, although, one usually predominates. These problems can stem from congenital
or acquired sources, but regardless of the condition’s origin, diseased valves eventually
contribute to an increased load on the heart, a common precursor to heart failure [32].
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Diseased heart valves can often be diagnosed simply by listening to the heart.
Disruptions in the regular flow produce irregularities in the normal sounds of the heart,
which can be heard using a stethoscope. Diseases most commonly affect the aortic and
mitral valves on the left side of the heart. Failure of the right side of the heart is usually a
consequence of left-sided failure and is rarely an isolated incident. Valve disease, along
with contributing factors such as heart tissue damage and hypertension, create an
increased load on the heart forcing the heart to adapt to counteract. This adaptation
involves hypertrophy of associated myocytes as well as disruption of the normal structure
and composition of heart cells and extracellular matrix. If left untreated, continued
presence of hypertrophy will commonly lead to heart failure [32].

Figure 7. Path to cardiac dysfunction [32].
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1.3.1. Congenital Valve Defects
Congenital heart valve defects exist at birth and are not caused by environmental
factors, such as diet, lifestyle, or aging. The most common congenital heart valve defects
affecting the general population are bicuspid aortic valve and mitral valve prolapse
(MVP) [11,32,33]. MVP is associated with various inherited disorders; however, the
underlying disease mechanisms are not well understood and it may also be an acquired
disease [11]. MVP affects up to 3% of the population and is usually asymptomatic
leading to discovery during routine examinations [11,32]. Congenitally bicuspid aortic
valves are similarly common, only affecting 0.5 to 2% of individuals [11,32,33]. In
addition to defects that directly affect the valves, more systemic disorders can also cause
valve dysfunction. These include, but are not limited to, autoimmune diseases and
connective tissue disorders such as Marfan syndrome.
Mitral valve prolapse is described as a floppy mitral valve that overextends back
into the left atrium during ventricular contraction.

This disease is also called

myxomatous degeneration of the mitral valve, due to the presence of a thickened
spongiosa resulting from myxomatous material deposition [11,32].

This deposition

causes the leaflets to become hooded, thick, and rubbery and is accompanied by a
weakened fibrosa [32]. This disease occurs more often in young women and, though
mostly asymptomatic, can cause valve insufficiency and lead to serious complications
[11,32]. However, even asymptomatic mitral valve prolapse has recently been linked to
serious harmful cardiovascular events including heart failure and death [11].
A bicuspid aortic valve is defined as an aortic valve that appears to only have two
leaflets instead of the normal three. This abnormality can appear as one normal cusp and
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a second cusp that is composed of two cusps fused together or, much less commonly, two
symmetric cusps without signs of fusion. At early ages, this defect is also commonly
asymptomatic.

However, bicuspid aortic valve presence predisposes individuals to

certain complications later in life, such as aortic root dilation, cusp prolapse, accelerated
valve calcification, and increased susceptibility to infective endocarditis [32,33].
A

B

Figure 8. [A] Depiction of bicuspid aortic valve [33].

[B] Severe hooding and

calcification in a patient with mitral valve prolapse [32].

1.3.2. Acquired Valve Diseases
Acquired diseases are those that are attributed to factors after birth, but can be
affected by congenital disorders. Even though these diseases are acquired later in life,
some congenital disorders can predispose individuals to certain acquired diseases or
promote the progression of these diseases after they are contracted. These diseases may
also be influenced by lifestyle choices, such as diet, activity level, drug use, stress, and
surgical procedures. The primary acquired conditions that will be discussed in this
section are rheumatic heart disease, infective endocarditis, and degenerative diseases.
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Rheumatic heart disease (RHD) manifests as valvular defects due to an
autoimmune response by the body. Development begins with the contraction of group A
β-hemolytic streptococci bacteria and, although considered an acquired disease, genetic
factors also play a role in its development [32,34,35]. Following infection, antibodies are
produced by the body’s immune system to react with bacterial antigens. In susceptible
individuals, these antibodies are also reactive with certain tissue proteins and can target
the heart, joints, or central nervous system [32,35]. This is called rheumatic fever and
clinical expression occurs 2-3 weeks after the end of the initial streptococcal infection
[32]. Only 30-45% of rheumatic fever cases affect the tissues of the heart, while a much
larger portion (75%) affects the tissues in the joints. This disease has been largely
eliminated in industrialized nations.

However, it still remains a large problem in

developing countries and accounts for close to 250,000 deaths annually worldwide [35].
Infective endocarditis (IE) involves the growth of bacterial colonies on the heart
valves and over 80% of cases are caused by particular strains of streptococci,
staphylococci, or enterococci.

These particular microorganisms have the necessary

surface adhesins to overcome the hurdle of attachment to the heart valves and
surrounding structures. IE can affect individuals with previously normal healthy valves,
but valve damage promotes bacterial attachment at the site of injury [36]. Congenital
valve defects, degenerative valve disease, rheumatic heart disease and mechanical wear
all cause such valve damage. Intravenous drug users are also at a very high risk for IE, as
well as people who recently had catheters or other surgical procedures and patients with
prosthetic heart valves. The severity and speed of disease progression varies depending
on virulence of the organism. Highly active organisms lead to rapid tissue destruction
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causing obvious problems of valve insufficiency and heart failure [32,36,56]. More
benign growths can lead to large vegetations that interfere with normal valve function
causing leakage or stenosis [56]. In addition, large growths can form infected emboli that
cause downstream destruction via local tissue necrosis and infection [32,36,56].
Degenerative valve diseases are those that occur passively with the wear and tear
that accompanies age and most commonly include floppy damaged valves, aortic
dilation, and valve calcification [37].

Individuals who experience congenital and

acquired diseases that cause valve damage or increase the wear of valve tissues are more
likely to develop these degenerative diseases and experience faster disease formation and
progression.

For example, individuals with bicuspid aortic valves develop aortic

calcification up to two decades earlier than those with normal valves and are more prone
to aortic dilation [11,32,37-39].
The calcification and thickening of the aortic valve is defined as aortic sclerosis
and is present in over 25% of individuals older than 65 years of age [11,38,39]. Aortic
sclerosis shares many developmental characteristics with atherosclerosis and is similarly
influenced by hypercholesterolemia, hypertension, gender, diabetes, smoking, sedentary
lifestyle and age. Aortic sclerosis can develop into calcific aortic stenosis, the most
common cause of aortic stenosis [38-40]. Aortic stenosis is the most prevalent heart
valve disease affecting 43% of patients with valvular heart disease [41].
Although valve calcification is still discussed as a degenerative disease, it has
recently been discovered to also be an active process. This active process is due to
macrophage activity and a shift in VIC phenotypes that causes them to express properties
similar to osteoblasts, which are bone-producing cells [11,38,39,42]. Calcification of
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valves is of particular interest in research due not only to its prevalence in native valves,
but also because it is a primary mode of failure in prosthetic valves.
Together, each year, valvular heart diseases lead to the hospitalization of 93,000
Americans and are considered the primary cause of death for over 21,000 Americans.
These diseases are also a major contributing factor in an additional 43,000 American
deaths annually, not including instances of bacterial endocarditis or rheumatic fever.
This problem becomes compounded in an aging population as the prevalence of valvular
diseases is only 0.7% in individuals of ages 18 to 44 as compared to 13.3% in individuals
75 years or older [41]. Although valvular diseases are responsible for many deaths,
numerous lives are saved by surgical intervention through heart valve replacement and
repair. There are over 290,000 heart valve replacements performed every year worldwide
with the demand increasing at a rate of 10 – 12% per year [43]. Current heart valve
replacements are sufficient enough to prolong life in many cases, but they have their
limitations and cannot yet be considered an equal replacement of the native valve.

1.4.

Artificial Heart Valves

There are four primary types of prosthetic heart valves currently being researched
that will be discussed in this section: mechanical valves, biological valves, polymeric
valves and tissue engineered heart valves. Of these four types, mechanical valves and
bioprosthetic valves are currently the only ones available for use and each of these has
their various benefits and drawbacks. Since a perfect valve replacement has not yet been
produced, valve type selection is a matter of balancing pros and cons. When evaluating
the performance of an artificial heart valve it is important to keep in mind the criteria
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necessary for an ideal valve substitute. The list is daunting, but a summary of these
characteristics is displayed in Table 1, originally stated by Harken in 1962 [44].

Table 1. Desirable Characteristics of a Heart Valve Substitute [5].
Nonobstructive (Not stenotic in any way)
Quick and complete closure (No valve insufficiency or regurgitation)
Nonthrombogenic
Resistant to infection
Inert in the body (No inflammation or immune response)
Does not cause blood damage
Durable for the lifetime of the patient
Easily and permanently implanted
Tissue interface with the implant heals properly (No tissue overgrowth)
Not annoying to the patient (Noise free)

1.4.1. Polymeric Heart Valves
Polymers possess a wide range of properties that can vary based on molecular
subunit types, subunit order, presence of cross-linking, molecular weight of
macromolecules and the type processes used for manufacturing. We have the ability to
control all of these things to a certain degree, allowing us to widely control the properties
of polymeric materials and cater them to our specific needs. Many polymeric materials
are well tolerated by the body and are commonly used in the medical industry for a
variety of applications. In fact, polymeric materials are present in many cardiovascular
devices such as catheters, vascular grafts, stents, blood oxygenators as well as current
artificial heart valves in the sewing rings.
Polymeric heart valves are a promising topic of research with potential to produce
valves that combine the best properties of current prosthesis types.

The

hemocompatibility of many polymeric valves is superior to mechanical heart valves and,
likewise, there are materials available that are more durable than biological tissues [45].
However, developing a polymeric material with the proper combination of suitable
23

properties is a difficult task. Many polymers have been tested in order to find a suitable
material for heart valve production, but polyurethanes have attracted particular interest
due to their unique structure [45,46].
Polyurethanes have a two-phase structure of hard (crystalline) and soft (elastic)
molecular subunits that gives them a favorable blend of compliance and strength [45,46].
This allows polyurethanes to closely match the stiffness of natural vessels, which is one
basis of interest for their use in improved vascular grafts [47]. Polyurethanes also have
excellent hemocompatibility, but studies using polyurethane in cardiovascular devices
have suffered from durability problems with both in vivo and in vitro testing [45-47].
A

B

C

Figure 9. [A] Polyetheretherketone trileaflet valve. [B] Polycarbonate urethane trileaflet
valve. [C] Polycarbonate urethane bileaflet valve [54].

Recent research of polyurethane materials has mainly focused on using different
soft (elastic) segments to improve the long-term durability [45,46]. First generations
attempted to use polyesters and polyethers; however, these materials degraded due to
hydrolysis and oxidative damage. The use of polycarbonates solved some problems of
these previous generations, but currently experience problems with valve calcification.
More current polyurethane materials have shown promising results, but no polymeric
materials are currently approved for prosthetic heart valve use [45,47].
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Table 2. Summary of polymeric materials in prosthetic heart valve research [45].

1.4.2. Tissue Engineered Heart Valves
The basic premise behind this approach involves the use of a degradable threedimensional scaffold upon which host cells are intended to grow. Cells may be intended
to infiltrate in situ, or tissue regrowth may occur partially or fully in vitro. The host’s
cells will eventually completely infiltrate the scaffold as it breaks down leaving behind
only the living tissue. Ideally, this type of valve would be functionally identical to the
healthy native valve resulting in the perfect valve replacement [5,6,11,26,46,54].
The material requirements for heart valve tissue engineering scaffolds are
numerous and demanding. The scaffold itself must be a suitable valve replacement in its
own right. It must meet all mechanical and biocompatibility requirements of current
valve prostheses, with the exception of durability. This is to ensure that it can support
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itself until cell infiltration is complete and the resulting tissue can function on its own. It
must also support cell growth and degrade at a suitable rate to allow remodeling and
regeneration [26,46,64]. Most importantly, at no point during the tissue regeneration
process can mechanical failure occur, or death of the recipient is almost certain.
Materials from both natural and synthetic sources have been investigated as
possible candidates for suitable tissue engineering scaffolds. The benefit of using natural
materials is obvious since they offer a more familiar environment for cellular ingrowth
[11,46].

Collagen, fibrin and small intestinal submucosal matrix along with

decellularized xenogenic and allogenic valves are among some of the promising
prospects, but so far none have emerged as a suitable material [46]. Human trials were
attempted using tissue engineered decellularized porcine heart valves; though, these
resulted in early failure [11,26,46,65].
This scaffold, SynegraftTM, developed by CryoLife Inc. performed well in animal
studies using the porcine model. Structurally whole valve cusps were found in valves
explanted after 5 months. These valves showed significant host cell infiltration and
lacked any signs of valve calcification [26]. Similar implants in the sheep model also
demonstrated good results in three and six month explants [66]. However, implantations
of four SynegraftTM valves into children were disastrous. Three of the children died at
seven days, six weeks, and one year postoperatively while the last valve was explanted
after only two days. The explanted valves showed signs of severe inflammatory response
and experienced no cell repopulation. These devastating results call into question the
reliability of results from current animal models and will have far reaching effects on
future trials of any tissue engineered heart valves [65].
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The use of synthetic materials is based around developing biodegradable polymer
scaffolds. The ability to control many mechanical properties of these scaffolds as well as
the degradation characteristics makes this approach particularly appealing. Polylactic
acid (PLA), polyglactic acid (PGA), poly-4-hydroxybuturate (P4HB), polycaprolactone
(PCL), polyurethanes (PUs), and their copolymers are some commonly investigated
materials for use in synthetic scaffolds [26,54,64,67]. Hoerstrup et al. created scaffolds
from PGA and P4HB that were seeded and implanted at the pulmonary position in the
sheep model. These valves remained functional for 20 weeks and the typical tri-layered
structure of the native valve was present in explanted valves. However, these valves also
showed mild regurgitation and incomplete endothelial cell coverage [26,54,68].
The hope of tissue engineering research aims at creating the perfect heart valve
replacement. Perfection of this technology could lead to the creation of a working living
valve with lifelong durability that can remodel, repair, and grow with the patient. Many
good results have made us optimistic; however, catastrophic results have also made it
obvious that many obstacles still remain.

1.4.3. Mechanical Heart Valves
Mechanical heart valves (MHVs) are those made entirely from synthetic
materials. However, for the purposes of this review, this excludes polymeric valves and
tissue engineering scaffolds. All mechanical heart valves consist of three major parts: the
occulder, valve housing, and sewing ring. The occluder is the only moving part of the
valve that blocks and opens blood flow. The housing is the primary structure that
maintains the integrity of the valve as well as provides vital guidance for the occluder.
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The sewing ring is a flexible fabric, usually made from ePTFE or Dacron, and is used for
attachment of the valve to the body. The main benefit of mechanical heart valves is their
durability.

Current valves have proven to be extremely long lasting and cases of

structural failure are extremely rare [48]. However, the nature of MHV materials and
geometries cause them to express lower hemocompatibility and patients that receive them
must undergo strict lifelong anticoagulation therapy.
The level of required anticoagulation therapy is high and given the harshness of
the required warfarin therapy, elderly patients, patients with bleeding disorders, or
women who are pregnant or planning on conception should not be recommended for
MHV replacement. This makes MHVs the replacement of choice for patients with a long
life expectancy where anticoagulation therapy is not contraindicated [43,48-51].
However, even when MHVs are recommended, anticoagulant therapy is still undesirable
and carries with it the risk of harmful side effects [49].

1.4.3.1.

Background of Valve Types

The birth of mechanical heart valves occurred in 1952 with the implantation of a
valve designed by Dr. Charles Hufnagel. This valve was not implanted at the site of the
diseased aortic valve, but was instead inserted into the descending thoracic aorta
[48,50,51]. The Hufnagel valve consisted of a silicone rubber coated nylon ball inside of
a methacrylate chamber. This device was not a true valve replacement and was only
designed to treat aortic valve insufficiency. The introduction of the Hufnagel valve was
soon followed by the caged ball valve, which was the first device designed to actually
replace the native valve [50].
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Caged ball valves use a ball as the valve orifice occluder that is retained in a cage.
After this evolution in design, there have been essentially no mechanical failures
associated with these valves after over 250,000 implantations [48]. Problems associated
with the caged ball valves include their bulkiness and risk of thrombus formation. These
large valves are centrally occlusive to the bloodstream leading to high transvalvular
pressure gradients and highly abnormal blood flow. Switching to the use of a disc
occluder in caged disc valves proved to be less bulky; however, these also caused high
central blockage of normal blood flow and experienced high complication rates, which
sparked the development of tilting disc valves [50].
Tilting disc valves exhibit marked improvement over previous designs with
respect to central flow and hemodynamics. These valves utilize protruding struts to tilt
the disc during the open phase allowing better central flow [49,50]. The development of
these valves coincided with the discovery of smooth pyrolytic carbon as an extremely
tough, thromboresistant material, which quickly became the material of choice for the
majority of all succeeding mechanical replacements [48,50,51].
The current gold standard of mechanical heart valve replacements is the bileaflet
valve. When compared to other mechanical heart valves, bileaflet valves display a much
flatter velocity profile and are heralded as the most hemodynamic valves available today.
These valves utilize hinges built into the valve housing to guide the rotation of two half
disc, semi-circle shaped occluders. This eliminates the need for protruding struts for
occluder guidance making bileaflet valves the most compact valves offered. These
valves have experienced enormous success and currently account for over 80% of
implanted MHVs [43].
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1.4.3.2.
1.4.3.2.1.

MHV Failure
Thrombus Related

Today’s mechanical heart valves are primarily composed of pyrolytic carbon, and
although relatively inert in the body, is still a foreign material and can initiate blood
coagulation through the intrinsic pathway [52]. This problem is compounded in areas
where stagnant flow is prevalent or where recirculating flow gives time for coagulation to
occur. Other flow abnormalities and high-risk areas for hemolysis and platelet activation
further increase the risk of thrombus formation via the extrinsic pathway [43,49,52].
High-risk areas include regions where blood experiences high shear stress and places
where blood damage occurs due to the closing of mechanical structures [43]. Once
thrombus is formed it can attach and interfere with valve function or embolize and cause
problems downstream. The overall incidence rate of these complications is 0.3% -1.3%
and 0.6% - 2.3% per patient year, respectively [49].

1.4.3.2.2.

Anticoagulant Related

Patients who receive an MHV replacement are required to undergo warfarin
therapy to reduce the risk of thrombus related complications.

The level of

anticoagulation required by a patient is measured using INR, which stands for
international normalized ratio. This is a ratio of the patient’s blood clotting time in
reference to normal clotting time and must be monitored closely [53].

Since

anticoagulant therapy increases the risk of bleeding complications, attempts are made to
administer the lowest therapeutic amount. Still, anticoagulant related hemorrhages occur
at a rate of approximately 1% per patient year [49].
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1.4.3.2.3.

Pannus Overgrowth

Failure from pannus overgrowth occurs when a hyperplasic tissue response causes
abnormal growth across the sewing ring [54]. Chronic inflammation at the site of the
implant causes macrophages to merge into multi-nucleated foreign body giant cells in an
attempt to phagocytose the valve material [55]. This inflammatory response triggers the
release of various growth factors and cytokines that prompt sustained tissue growth. The
end result is tissue hyperplasia and a myointimal protrusion that causes narrowing of the
lumen or prevention of normal valve function [54,55,89]. This occurs mainly on the
ventricular side of aortic valves and is the primary cause of valve obstruction being much
more common than thrombus related interference [54].

Figure 10. [A] Obstructive thrombosis in tilting disc valve. [B] Obstructive pannus
overgrowth in bileaflet valve. [C] Strut fracture in Björk-Shirley tilting disc valve. [49]

1.4.3.2.4.

Infective Endocarditis

Patients with prosthetic valve implants are predisposed to contraction of infective
endocarditis, particular in the early post-operation period [36,56]. The incidence rate of
infective endocarditis is similar in mechanical and bioprosthetic heart valves and is
associated with a patient mortality rate of approximately 50%, even with surgical and
medical intervention [32,56]. The disease itself is similar to that of the native valve and a
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detailed discussion is provided in section 1.3.2.

However, in mechanical valves

organisms cannot attach to the surfaces of the valve structure itself, which cannot be
destroyed. Attachment to the surrounding annulus and sewing ring is still possible, that
can lead to detrimental tissue destruction and vegetation growth [56].

1.4.3.2.5.

Patient Prosthesis Mismatch

Rahimtoola first described patient prosthesis mismatch (PPM) in 1978 and this
phenomenon has been associated with increases in valve replacement mortality rates.
PPM is used to describe circumstances where a patient has received a valve prosthesis
that excessively impedes blood flow below the amount required by the patient [54,57].
High transvalvular pressure gradient is the primary consequence of PPM. This increases
the workload of the heart and prevents regression of ventricular hypertrophy. These are,
as mentioned before, common precursors to heart failure [32,57]. The indexed effective
orifice area (EOAI), a common predictor of PPM, should ideally be no less than 0.85 to
0.90 cm2/m2 in order to avoid PPM complications [43,57].

Qrms

(

2
EOAI cm

m2

)

=

51.6 Δp
BSA

BSA = Body Surface Area
Qrms = Root mean square systolic/diastolic flow rate
Δp = Transvalvular pressure drop [43,57]

€
Figure 11. Equation for indexed effective orifice area.
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1.4.3.2.6.

Structural Failure

Structural failure in mechanical heart valves is extremely rare. Many models
have experienced hundreds of thousands of implantations without experiencing a single
instance of structural malfunction. However, certain models have been known to produce
small, but significant, amounts of valves that succumb to some form of structural failure.
Failure modes have included leaflet fracture, strut fracture, and leaflet escape [48].
Mechanical failures in MHVs are primarily attributed to three causes [54]:
•

Elevated closing load that exceeds the valve material’s fatigue strength.

•

Material fatigue

•

Cavitation (Phenomenon that causes erosion and pitting via microbubbles [61].)

Experience from past models has lead to increased knowledge about these failure modes
sparking necessary material and design improvements. For this reason, structural failure
of MHVs has been largely abolished and continued efforts aim to eliminate it completely.

1.4.3.3.

Current Developments

Current developments in MHVs aim to improve upon flaws in fluid mechanics by
altering the structural designs. This will hopefully lead to increased hemocompatibility
and, in turn, the amount of required anticoagulation therapy. The ATS Open Pivot® is a
recent innovative bileaflet valve that claims to possess an improved hinge design. This
valve has undergone trials with patients adhering to reduced anticoagulation (INR = 1.5 –
2.5) with good results [58]. Also, trileaflet valve designs are now emerging that promise
better central flow, improved hemodynamics, lower impact stresses, lower amounts of
regurgitation, and reduced risk of cavitation [59,60].
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1.4.4. Biological Heart Valves
Biological heart valves are those that are fully or partially composed of biological
tissues and include those derived from both human and xenogenic sources. Other than
mechanical heart valves, bioprosthetic heart valves (BHVs) are the only other
replacement option currently available. These valves are hemodynamically superior to
MHVs due to their anatomical and physiological similarities, and do not require
anticoagulation therapy. Even so, the rate of thrombus related complications for BHV
recipients is similar to that of MHV patients under full anticoagulant therapy [5].
However, biological valve replacements are far less durable with the majority of valves
succumbing to structural dysfunction within 12-15 years [62].

1.4.4.1.

Human Tissue Valves

Human tissue valve replacements consist of allografts (a.k.a. homografts) and
autografts. Allografts are typically cryopreserved aortic valves that come from organ
donors or cadavers [62,69]. The most common cryopreservation technique involves the
use of 10% dimethyl sulfoxide (DMSO) as a cryoprotectant prior to storage in liquid
nitrogen.

However, it is debated whether the use of cryoprotectants improves cell

viability or properly preserves ECM components [63].

Regardless, these valves

experience extremely good hemodynamics, but suffer from problems with long-term
durability, as with all biological valve replacements [62,69].
The most common form of autograft occurs when the patient’s diseased aortic
valve is excised and their pulmonary valve is relocated to the aortic position in its place.
This method is referred to as the Ross procedure and is normally used in children with
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diseased aortic valves. This form of replacement gives the child a living aortic valve
replacement of his or her own tissue with the ability to repair, remodel, and grow with the
patient. However, a cryopreserved pulmonary valve allograft is still used in this case,
which carries with it issues of long-term durability [62,69]. Regardless, this procedure
may still be beneficial for children considering the drawbacks of pediatric BHV or MHV
aortic valve replacements.
Both allograft and autograft procedures allow the patient to have freedom from
anticoagulation therapy without significant risk of thrombus related events. However,
they both also suffer from eventual structural degeneration and lack of long-term
durability.

These advantages and disadvantages are present for all biological valve

replacements, though drawbacks of human tissue valves also include low availability
[62,69].

Allografts and autografts may have their place in certain patients and

procedures, but with the increasingly large volume of valve replacement procedures
performed each year, this option cannot be viable as a solution for the general public.

Figure 12. Aortic Homograft after preparation [69].
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1.4.4.2.

Xenogenic Tissue Valves

Currently, there are two primary types of xenogenic tissue that are used in BHV
fabrication. These include valves made from whole porcine aortic valves (PAVs) and
those crafted from cuts of bovine pericardium (BPVs) [5,6,71]. Since xenogenic tissue is
subject to severe immune rejection, the tissue antigenicity must be removed prior to
implantation. Glutaraldehyde treatment sufficiently diminishes tissue antigencity as well
as crosslinks the tissue, which protects against proteolytic degradation [5,71].
Glutaraldehyde treatment of these valves is standard, but treatment methods and valve
designs can vary greatly. There are many BHV models available today and, although
widely studied, it is still largely unclear which valves yield the best clinical results.

1.4.4.2.1.

Mounting Types

Valves of each tissue type can be mounted on a stent or manufactured without.
BHV stents vary by model, but are made from metal or plastic covered in fabric and
typically have three posts with a sewing ring around the base [5,6,71,72]. Rigid metal
stents were initially used, however, tears at the commissures in proximity to the posts
sparked a movement towards the use of flexible stents. These mostly polymeric stents
still failed to the same tears, but now also suffered issues from stent creep and
deformation.

For the most part, this has now been eliminated due better material

selection and technology, but the benefits of flexible stents are still debatable [71].
Stents are used to make valve handling easier, helping to maintain proper leaflet
shape and alignment from the time of manufacture. This stability makes valve function
more predictable allowing valves to function in the patient as they would in vitro.
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Surgical implantation of stented valves is also much less technical, as these valves are
relatively easily attached to the annulus using sutures [71]. Although the use of stents has
many benefits, the resulting increased profile reduces valve EOA.

This creates

undesirable transvalvular pressure gradients and has sparked the use of stentless BHVs.

A

C

B

Figure 13. Various stented BHV valve designs. [A] Hancock IITM (PAV)

[B]

Carpentier-Edwards (PAV) [C] Perimount (BPV) [73].

The benefit of stentless BHVs lies simply in its ability to use a larger valve size
than a stented valve for any given patient.

This increases the EOA of the valve

replacement, lowering transvalvular pressure gradients and better supporting ventricular
mass regression [5,71].

In fact, a short-term follow-up demonstrated 30% lower

ventricular mass index in patients implanted with stentless valves [74]. However, these
valves lack the benefits of stented valves and are much more difficult to handle and
implant. There is also evidence that these valves will be more prone to failure from
aortic wall calcification and pannus overgrowth. This is because increased proximity and
contact of the xenogenic wall tissue with the host may additionally increase
immunological and inflammatory responses [5]. The clinical benefit of stentless valves is
promising but uncertain and only the most highly skilled and experienced surgeons can
perform implantations [71]. For these reasons, more follow-up studies are needed to
justify the increased technical difficulties that accompany these valves.
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Figure 14. Various stentless BHV valve designs. [A] Freedom Solo, Sorin Group (BPV)
[B] Prima Plus, Edwards (PAV) [C] NR200, Shelhigh (PAV) [73].

1.4.4.2.2.

Tissue Types

The use of porcine aortic valves to construct BHVs is possible due to the high
amount of similarity between human and pig cardiac anatomy. In pigs, a muscle shelf
supports the right coronary cusp and there is a lesser extent of mitral valve to aortic valve
fibrous continuity, but otherwise, the aortic valves of humans and pigs are very
comparable [70,72]. Valves made from porcine aortic valves (PAVs) use the aortic valve
cusps and varying amounts of aortic wall. The primary structure of PAVs is based on the
normal anatomy and remains mostly the same between models; however, there are still
many variations in design as can be seen in the figure above (Figure 15: B and C).
Stented PAVs differ primarily in stent material and stent design. The fabric
coverings and sewing rings are made from Dacron and PTFE with the occasional
additions, such as silicone inserts. The stents themselves are made from various metals
and polymers and most resemble the typical three-post design (Figure 14).

However,

some valves display vast differences in stent design, such as the BioImplant PAV valve
that attempted a vast reduction in stent profile (Figure 16). Some valves also incorporate
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metals into their sewing rings or stents to render them radioopaque [72]. Most stentless
PAVs have very minimal additions to the aortic root or any portion of the porcine aortic
valve, although some of these valves have minimal cloth coverings and diagrams that aid
in trimming, fitting, and implantation [72,74]. Lower transvalvular pressure gradients,
better LV mass reduction, and less structural tissue failure has been seen in stentless
PAVs, but additional follow-up studies are still needed to validate these benefits [74].
As mentioned above, there is a muscle shelf supporting the right coronary cusp of
the porcine aortic valve that is an extension of the ventricular septum [5,70]. This muscle
tissue inhibits valve motion and is thought to be a promoting site for calcium deposition
[5,71,72]. Therefore, in an effort to reduce these ill effects, some PAVs remove this
valve cusp and replace it with an essentially congruent cusp from another valve. This
type of PAV is referred to as a composite valve. Other variations of composite valves
include tricomposite valves, which use three noncoronary cusps from separate valves. In
this design, cusps are matched up for proper geometries to achieve optimal coaptation
[5,71,72].

These valves have shown fine clinical performance, but more follow-up

studies are needed to determine the long-term benefits of this approach [71].

Figure 15. Low-profile stent PAV, BioImplant [71].

39

Like the porcine aortic valve cusp, bovine pericardium is a specialized tissue with
three distinct layers. The inner layer that faces the heart is a smooth layer protected by
visceral mesothelium.

The middle fibrosa layer contains collagen, elastic fibers,

vasculature, lymphatics, and nerves that comprise the majority of bovine pericardial
tissue thickness. Loosely arranged collagen and elastic fibers are abundant in the outer
layer, which must be cut away from tissue that surrounds the heart. This trimming leaves
the outer layer rough, especially when compared to the smooth visceral side. Pericardial
BHVs are constructed so that this rough outer layer is positioned facing the inflow. This
is to ensure that the rough pericardial surface is thoroughly washed, which helps to
prevent thrombus related complications [5].
Sheets of bovine pericardium permit the production of virtually any needed shape
allowing for enormous play in BPV design. Since they are not set in their primary
structure, like PAVs, BPVs can make modifications as substantial as the number and
shape of the cusps. A very popular stented BPV design is a folded cylindrical design
(Figure 14: C) [71,72]. This design allows stented BPVs to be formed from multiple cuts
of pericardium or molded from a single section (Figure 17) [6,71].
BPVs may have slightly better hemodynamics than PAVs due to the completely
unobstructed flow offered by the cylindrical open position [71]. This may cause them to
express slightly slower degradation giving them superior durability; however, BPVs often
suffer from inferior biomechanics, making them prone to commissural tears and single
leaflet prolapse [71-73]. Despite claims of valve superiority for each type, current overall
rates of complication for both PAVs and BPVs are similar to that of MHVs, with a 5060% rate of death or reoperation after 10 years [5].
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Figure 16. [A] Diagram showing construction of a stented BPV [6]. [B] Picture showing
stented BPV construction from a single pericardium piece [71]. [C] Quadraleaflet
stentless BPV for mitral replacement, SJM Quattro [72].

1.4.4.3.

Bioprosthetic Heart Valve Failure

Failure in BHVs occurs differently between types, but there are general events
associated with contribution to valve failure that affects all varieties. These include noncalcific structural damage and deterioration, calcification, immunological and
inflammatory responses, paravalvular leaks, pannus overgrowth, infective endocarditis,
and thrombus related complications. Structural deterioration and calcification are the
primary contributors to BHV valve dysfunction, with the majority of BHVs succumbing
to some form of degenerative disease within 12-15 years [5,62].
Degenerative modes of BHV failure are highly age and time dependent with lack
of long-term durability, presenting the biggest drawback for BHVs, especially in younger
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patients.

Short-term experience in adults has been excellent with less than 1% of

implanted PAVs failing within five years. Failure rates increase to 20-30% at ten years
and are capped at around 12-15 years, at which point 50% of implanted valves fail.
These numbers are exacerbated in younger patients where nearly 100% of valves fail
prior to 5 years in individuals under 35 years old. When also considering that ten-year
failure rates fall to 10% in patients over 65, the age-dependence of BHV structural
degeneration rates becomes obvious [5,62]. Failures from degenerative sources are most
commonly expressed as valvular insufficiencies from cusp tears, affecting roughly 75%
of PAVs. Purely stenotic valves, due to cusp damage or stiffening, occur much less often
at a rate of approximately 10-15% [5].
Non-degenerative events also make contributions to valve failures and are
important, but thrombus related complications, pannus overgrowth, and infective
endocarditis are not discussed in this section. The rate of thrombus related failures in
BHVs are similar to that of MHVs in patients under full anticoagulant therapy. This is an
accepted risk, and when compared to other modes of BHV failure, this problem is minor.
Infective endocarditis rates are also similar in both BHVs and MHVs at 1-6% and
although this may still be cause for worry, thorough discussions of infective endocarditis
are already provided in sections 1.3.2 and 1.4.3.2.4 [56]. Pannus overgrowth was also
discussed earlier in section 1.4.3.2.3, but section 1.4.4.3.3 provides further discussion.
All in all, the underlying cause for most modes of valve failure remains the loss of cell
viability within BHVs. This disallows normal healing and repair patterns as well as
removes the ability for the maintenance of cellular and extracellular matrix homeostasis;
all of which are critical to preservation of normal valve function.
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1.4.4.3.1.

Structural Deterioration (Non-calcific)

Gradual structural deterioration of BHVs occurs primarily due to changes in
natural valve biomechanics and loss of cell viability. These changes cause localized
stresses in the tissue that can eventually lead to dysfunction in the form of tissue buckling
or cusp tears [5].

This localized damage may progress slowly, but progresses

unrestrained since BHVs lack the ability for repair. Although this form of cusp damage
is sometimes difficult to discern from calcific effects, since they often occur together,
non-calcific structural deterioration has been shown to play a major role in BHV failure,
independent of calcification [81]. In fact, roughly 90% of PAVs fail from some form of
structural damage with many showing little to no signs of calcification [76].
The initiation of tissue deterioration begins before implantation, during tissue
harvesting and preparation where glutaraldehyde fixation is thought to play a large role.
Glutaraldehyde causes loss of cell viability and, upon cell death, ECM degrading
proteases may be released, which cause irreparable damage to the ECM ultrastructure.
Degradation of collagen fibrils has been observed after fixation, as well as loss of
collagen associated GAGs and PGs [75]. Increased levels of ECM degrading enzymes
have also been observed in explanted valves, which further contribute to collagen damage
and loss of GAGs [82,83]. Glutaraldehyde treatment does not fully prevent enzymatic
activity and both early and chronic enzymatic presence could have devastating effects on
ECM integrity [5]. Given the fact that loss of cell viability also eradicates the ability for
ECM repair, current methods of tissue preparation seem inadequate to sufficiently protect
the ECM in BHVs.
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Changes in valve biomechanics also begin with glutaraldehyde fixation.
Glutaraldehyde effectively removes tissue antigenicity and cross-links collagen to
support preservation of ECM integrity.

However, formation of collagen cross-links

paired with lack of ECM remodeling capability results in a locked ECM architecture that
is unlike its natural dynamic state [84,85]. This results in irregular cusp movement and
increased cusp rigidity that cause increased stresses, principally at points of high tissue
flexion [5,77]. In PAVs, this is compounded by the loss of GAGs from BHV cusps,
which help cusp tissue cope with high compressive stresses. Glutaraldehyde treated
BHVs have been shown to lose GAGs both in vitro and in vivo [19,30]. GAGs in the
spongiosa also provide a shear stress dissipating buffer layer that accommodates motion
between the ventricularis and fibrosa.

Depleted spongiosa function has detrimental

effects on BHV biomechanical function and further promotes increased tissue stresses
and susceptibility to mechanical damage, such as delamination [5,15,18,31,77].

Figure 17. Progressive delamination due to cylic fatigue [77].
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1.4.4.3.2.

Calcification

Valve dysfunction due to calcification and related tissue damage is a prevalent
mode of BHV failure, second only to non-calcific mechanical damage [54]. Calcification
pathways are not all fully understood, though tissue damage, host responses, and implant
characteristics are all known contribute to the process. Calcification occurs in two phases
initiation/nucleation and propagation of calcific crystals.

Initiation most commonly

begins below the tissue surface and is referred to as intrinsic calcification [5,78].
Extrinsic calcification also occurs which can lead to thromboembolic complications, but
this is much more rare [78].

As calcific crystals propagate and coalesce, tissue

microstructure begins to deteriorate and stiffness and/or cusp tears may occur [5,75,78].
Calcification contributes to structural failure over time and affects the long-term
durability of BHVs. However, progression of calcification is greatly accelerated in
younger patients and also contributes to the high short-term failure rate for this group
[5,78]. Therefore, better understanding of how to prevent this mode of failure could
greatly expand upon the useful applications of BHVs.
Formation of calcific nodes in BHVs is thought to be a result of loss of cell
viability. Under normal circumstances, low intracellular calcium levels are maintained
during standard cell metabolic processes. Upon cell death, this ability is lost allowing
high concentrations of calcium to saturate remnant cell debris [5,75,78,79].
Mineralization begins when this influx of calcium reacts with sources of organic
phosphorus that remain behind, including that from organelles, nucleic acid backbones,
and cell membranes [78]. Red blood cells and inflammatory cells may also penetrate the
tissue and accumulate, providing additional nucleation sites for crystal growth [5].
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Cellular debris represents the most predominant nucleation site for BHV
calcification. Extracellular matrix components are also subject to calcification, although
modes are less understood [5].

Collagen fibers can serve as nucleation sites for

calcification, however, only after crosslinking with glutaraldehyde [5,62,75,78,79].
Elastin calcification also occurs, but does not depend of the presence of crosslinking
[5,75,78]. This may be a result of the loss of elastin-associated microfibrils, which shield
elastin from calcification.

These microfibrils are lost during tissue harvesting and

preparation, possibly due to enzymatic hydrolysis by fibrillin degrading matrix
metalloproteinases (MMPs). Conversely, glycosaminoglycans may inhibit calcification
by chelating calcium to prevent nucleation or sterically through structural interferences
with hydroxyapatite although this is controversial [75].

However, this has been

supported by studies in the rat subdermal model where GAG loss was shown to promote
calcification, whereas GAG fixation showed inhibition [86-88].
GAG retention may also reduce calcification through improvements in BHV
biomechanics.

Regions of increased mechanical stress are known to stimulate

calcification, and these areas regularly harbor calcium deposits in BHVs. Maximum
leaflet flexion occurs at the commissures and basal attachments, and both extrinsic and
intrinsic calcification is prevalent at these sites of severe tissue deformation [5,62,78].
Loss of GAGs and glutaraldehyde treatment are thought to increase susceptibility to
calcification; however, glutaraldehyde fixation is still a necessary standard for BHVs, and
GAGs are not preserved through this process.
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Figure 18. Flow of calcification as it progresses from nucleation to BHV failure [78]

A

B

Figure 19. [A] View of fibrosal side of porcine BHV showing calcification and tears
after 8 years of implantation in the mitral position [62]. [B] Movat Pentachrome stained
section of porcine BHV cusp showing calcification (9 years, aortic position) [62].
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1.4.4.3.3.

Inflammation and Immune Responses

The contribution of inflammatory and immune responses has been mostly ignored
as a source of BHV failure. It has long been known that standard glutaraldehyde fixation
using low concentrations does not eliminate antigenicity, but merely reduces it
(approximately by 59%) [5,54,90,91].

Even though antibodies against tissue

glycoproteins and inflammatory cells have been noted in failed valves, the link between
these responses and BHV failure has been unclear [5,89]. These subjects have recently
gained attention as being worth significant research, but the results of various studies
have been conflicting. Still, enough evidence has been put forth to warrant further
investigation into the role of inflammation and immune responses in BHV failure.
Remnant immunogenicity after BHV tissue fixation is a result of glutaraldehyde’s
failure to alter membrane bound receptors or structural glycoproteins [54].

This

insufficient removal of antigens is thought to result in an increased inflammatory
response that contributes to decreased durability in BHVs. Almost monolayer coverage
by inflammatory cells is found in most explanted BHVs, and it has been proposed that
this is caused by proinflammatory characteristics of glutaraldehyde itself [89,92]. This
has been refuted by many studies that demonstrate the use of increased glutaraldehyde
concentrations to completely suppress immunogenicity will greatly mitigate recruitment
of inflammatory cells [54,89]. Recruitment of phagocytes is proposed to occur via
chemoattractants released through opsonization.

This occurs through nonspecific

mechanisms via the system of circulating complement plasma proteins as well as through
more specific means that involve the humoral immune response and circulating
antibodies against BHV tissue glycoproteins [54,55,89].
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There is evidence that these phagocytes contribute to tissue damage leading to
BHV failure. Studies have shown that intense amounts of phagocytes inhabit valves that
have experienced failure from tearing [89,93,94]. Also, Dahm et al. demonstrated an
increased percentage of patients showing BHV component specific antibodies in failed
valves when compared to patients with functioning valves [95].

Direct observation of

collagen phagocytosis by macrophages using transmission electron microscopy (TEM)
was also found in 82% of failed BHVs [96]. To the same end, presence of digested
collagen was discovered in the cytoplasmic vacuoles of invading macrophages during
other studies [97].
Evidence has also suggested that inflammatory and immune responses play roles
in other modes of BHV failure as well. The inflammatory potential of BHV tissue may
add to the amplification of pannus growth [89]. This is supported by data showing a five
times reduction in pannus length after six months of implantation in the sheep model with
BHVs fixed using higher glutaraldehyde concentrations to suppress tissue antigenicity
and associated inflammatory response [98]. Various groups have also demonstrated links
to calcification. Vincentelli et al. showed a 35 times increase in calcification when
comparing implanted xenogenic tissue to autologous tissue in the sheep model [99].
Another study provides further evidence of tissue antigenicity’s role in calcification by
demonstrating that tissue from antigen knockout pigs expressed reduced calcification
after incubation in human antibodies when compared to normal porcine tissue [100].
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1.4.4.4.

Current BHV Research

Since structural damage and calcification are the primary modes of BHV failure,
most of the current subjects of BHV research concentrate on overcoming these obstacles.
Main areas of research include: new tissue fixation methods, new BHV materials, and
anti-calcification treatments. New fixation methods are currently being researched to
supplement, alter, or even entirely replace glutaraldehyde fixation. This approach aims to
improve the chemistry, micro-architecture, and biomechanics of the BHV ECM in order
to achieve better long-term preservation. The search for new BHV materials is similar in
that improved tissue structure and function is sought to achieve improved long-term
durability. In fact, porcine vena cava is currently being researched by a member of our
lab as a possible alternative to bovine pericardium.
Large investments of research have been placed on anti-calcification treatments
due to the relative ease of integration when compared to completely changing material or
fixation chemistries. Anti-calcification pretreatments primarily function by targeting the
first phase of clinical calcification, the nucleation of calcific crystals. This can be done
by using inhibitors to interfere with mineral development or through removal of sites
conducive to crystal formation. Biphophonates, amino-oleic acid, and trivalent metal
ions such as aluminum or iron chloride are used to prevent or inhibit calcium phosphate
crystal formation; while ethanol, decellularization processes, and surfactants are applied
to remove organic phosphates and other remnant cellular debris that is known to promote
valve calcification [5,12,78,80].
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Percutaneously implanted heart valve research represents a branch of improved
BHV design. Instead of focusing on improving the durability of BHVs, the use of these
valves merely enables us to better cope with current durability problems [54].
Insufficient durability of a BHVs leads to either failure of the valve or the need for
reoperation and replacement of the diseased bioprosthesis. Current replacement surgeries
are highly invasive and repeat operations are extremely undesirable. Application of
catheter based BHV delivery could drastically reduce surgery related patient morbidity
and mortality rates [102]. This would allow for easier replacement of diseased BHVs as
well as enable a wider range of the population to be acceptable BHV candidates [101].
The process involves crimping a BHV down to deliverable size and expanding it at the
desired site via a balloon expandable or self-expanding nitinol stent. Although simple in
concept, all aspects of implantation, including valve compression, delivery, and valve
function, present problems. However, new percutaneous valves are being developed and
this tactic seems to represent the next generation of BHV design [54,101,102].

A
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Figure 20. [A] Self-expanding nitinol pericardial BHV by CoreValve [101]. [B] Edwards
Sapien® balloon expandable BHV [101]. [C] Depiction of catheter and transapical access
in a BHV leaflet replacement procedure, ValveXchange® [54].
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1.5.

Heart Valve Biomechanics

Lack of durability is currently the primary drawback plaguing BHVs. Barring
recipient death or malfunction from less prominent sources, failure due to calcification
and/or structural deterioration is inevitable. Much of current BHV research has targeted
reduction of calcification through alternative fixation methods and anti-calcification
treatments. If anti-mineralization strategies progress to the point of 100% protection
against calcification, stability and preservation of the collagenous skeleton would then
become the limiting factor in BHV durability [122]. Already, 90% of current porcine
aortic valve BHVs fail due to structural damage, many without signs of significant
calcification [76,123]. As discussed previously, BHV tissues lack the ability to repair.
This causes all mechanical damage to be cumulative and leaves prevention as the only
solution [122]. This damage may also contribute to failure by facilitating proteolytic
degradation, further suggesting that prevention of this damage may be critical to
increasing the lifespan of BHVs [123].

The occurrence of this damage is highly

dependent on cusp mechanics. Investigation into the biomechanics of both natural and
fixed valves could provide not only insight into the mechanisms of structural degradation
but also supply a knowledge base for the development of prevention strategies [124].

1.5.1. Native Valve Biomechanics
Normal aortic valve function is primarily passive, naturally opening and closing
due to transvalvular pressure changes and direct interaction with the bloodstream.
However, the term ‘passive’ seems terribly inadequate when describing the complex
interactions occuring within the specialized tissue layers of aortic valve cusps during
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normal function.

Internally the tissue is very dynamic, constantly adapting to

accommodate the changing mechanical loads [4]. There are three loading modes that
accompany normal aortic valve function including tension, flexure, and shear. Tension
occurs most prominently during valve closure when the valve cusps must expand in order
to properly coapt. Shear forces are at their highest when the valve is open and blood is
rushing parallel to the surface of the ventricularis at high velocities, while flexure occurs
during the transitions [29].
Collagen, which is primarily found in the fibrosa, is the protein that most
effectively deals with tension. Proper coaptation is passively facilitated through the
characteristics and structure of collagen fibers in this layer.

The circumferentially

aligned collagen fibers provide resistance during full cusp expansion and help maintain
proper shape. These taut fibers prevent sagging and prolapse while also aiding in stress
transfer to the annulus [122]. The low resistance of collagen fibers to torsion and
bending imparts flexibility in the radial direction, which aids in dealing with rapid radial
strain changes. Macroscopic collagen corrugations as well as microscopic collagen crimp
also lend additional extensibility further enabling cusp expansion and mitigating incurred
stresses [4].
The natural curvature of aortic valve cusps is partly maintained by preload present
in the ventricular and fibrosa. The fibrosa is naturally loaded in compression while the
ventricularis is in tension [14,28]. The high elastin expression present in the ventricularis
utilizes this to provide elastic recoil, which aids in proper opening. This action also
minimizes contact with shear forces by reducing the available surface area during the
open state [5,11]. Flexure occuring during the transition phases causes internal stresses
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that are attenuated by the spongiosa. Uneven deformations between the ventricularis and
fibrosa cause high internal shear stresses to develop at the common boundary. The
hydrated GAGs within the spongiosa provide lubrication that alleviates these stresses and
promotes smoother bending. Areas of elevated bending that do manifest, harbor high
amounts of compressive stress. When left unabated, tissue buckling can occur at these
points of high stress causing tissue disruption that ultimately contributes to overall valve
failure [126].

However, the hydrated state of GAGs also allows for absorption of

compressive loads further providing protection against damage from flexure [15, 31,125].

1.5.2. BHV Biomechanics
During glutaraldehyde fixation many alterations occur to aortic valve cusp tissue
that may negatively affect tissue mechanics and, in turn, valve function and durability.
The formation of crosslinks is essential to the preservation of the collagen structures.
However, they also lock the microstructure into a static formation, which prevents the
structural rearrangements that accompany normal function.

The dynamic collagen

rearrangements occurring during normal function, along with extension of crimp, are
very responsive to transvalvular pressures. Rearrangement has been shown to lead to full
collagen alignment at pressures as low as 4 mmHg, while collagen crimp is largely
abolished by 20 mmHg [122].

Zero-pressure fixation is thought to minimize the

consequences of a static ECM by preserving collagen crimp and stress free arrangement.
While lower pressure fixation has been beneficial, it was demonstrated that the benefits
of fixation below 4 mmHg is lost early under normal function. Substantial alignment of
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collagen was shown to occur during the first 50 million cycles of in vitro, which also
correlated with decreased tissue extensibility [123].
Increased cusp stiffness also occurs as a result of the crosslinked, static ECM and
leads to increased compressive stresses during flexure. Areas of high flexural stresses
have been demonstrated to generally coincide with increased calcification and have been
stated by Broom to be the primary culprit of non-calcific tissue damage [124,127]. The
penalty of these compressive stresses is compounded by the loss of GAGs, which
diminishes resistance to tissue buckling [31]. Tissue buckling is further promoted by
increased internal shear stresses resulting from GAG loss, which may also induce
delamination of the tissue layers. The end result is the accumulation of damage to
collagen fibers that eventually leads to BHV failure [15,31,75,77,125].

1.5.3. Characterization of Biomechanics
Basic characterization of the mechanics of BHV tissue begins with uniaxial
tensile testing. When subjected to tensile loads, porcine aortic valve cusps display a nonlinear stress strain curve demonstrating two clearly separate phases of mechanical
response (Figure 22).

The initial low-stiffness response is dominated by elastin

contribution and presumably includes elastin stretching, collagen uncrimping, fiber
rearrangement, and extension of corrugations. The secondary high-stiffness response is
dominated by collagen’s input and the higher modulus in this phase is indicative of the
properties of extended collagen in tension.
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High-end (collagen) region:

Low-end (elastin) region:

Figure 21. Stress strain curve obtained from uniaxial tensile testing on fresh aortic valve
cusps in the radial direction.
Simple tensile testing yields important information on the general extensibility,
stiffness, and strength of the tissue. However, it is far from physiologic and cannot be a
sole indicator of full-scale valve performance. Biaxial testing overcomes some of the
downfalls of uniaxial testing and provides a more complete insight into planar tissue
mechanics [28].

This testing procedure enables coupled analysis of the anisotropic

behavior of the tissue, but again has its limitations. Flexural testing allows additional
insight into tissue mechanics during bending behaviors, providing more information on
the major deformation mode of aortic valve leaflets [128].

Studying the energy

dissipation during loading and unloading, or hysteresis, may also be beneficial as it can
shed light on the viscoelastic characteristics of the tissue [129]. This may be important in
illustrating the significance of GAG loss and preservation in BHVs as hyaluronan and
chondroitin sulfate have been demonstrated to affect the viscoelastic properties of the
ECM and associated fluids [130]. Together these tools can provide us with a very
comprehensive model for aortic valve cusp tissue mechanics.
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1.6.

Aldehyde Fixation Methods

1.6.1. Formaldehyde Fixation
Formaldehyde is a very commonly used biological tissue preservative for many
lab practices. It is water soluble up to a saturation point of about 40% and aqueous
solutions are commonly referred to as formalin. Prior to the induction of glutaraldehyde
as the “gold standard” fixative for BHVs, formalin treatments were also considered as
contenders. Like glutaraldehyde, formaldehyde crosslinks by reacting with the amine
groups present on collagen molecules within BHV tissue. Tissues treated with formalin
solutions in concentrations from 0.5% to 10% were found to possess the desired tissue
stability for BHV construction. However, since formaldehyde is only monofunctional,
the collagen crosslinks formed are unstable and can be reversed under dynamic
conditions and during storage.

This phenomenon lead to unsatisfactory long-term

performance of formalin treated BHVs, heralding glutaraldehyde as a much superior
BHV fixative. Still, the low concentrations of glutaraldehyde used for BHV fixation can
be insufficient to completely sterilize the tissue, leaving formalin treatment to remain in
use as a post-fixation step for glutaraldehyde fixed BHVs.

Figure 22. Simplified representation of collagen crosslinking by formaldehyde [103].
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1.6.2. Glutaraldehyde Fixation
Glutaraldehyde is a water soluble, bifunctional aldehyde that is currently the
industry standard fixative for bioprosthetic heart valve tissue. Glutaraldehyde renders
BHV tissue resistant to autolytic degradation by the creation of Schiff-base crosslinks
between primary amines present on lysine and hydroxylysine of collagen molecules
[5,103]. Glutaraldehyde is also able to polymerize through aldol condensation, allowing
the formation of crosslinks of variable length [103]. In addition, partial sterilization and
immunogencity masking is accomplished through glutaraldehyde treatment, which is
necessary to prevent infection and immune rejection [5,6,54,71]. Various glutaraldehyde
treatments have been used since the 1960s and continue to demonstrate their
effectiveness, with the majority of adult implanted glutaraldehyde fixed BHVs currently
lasting 12-15 years before failure [62,103]. However, glutaraldehyde fixation has been
linked to various modes of BHV failure and this process has repeatedly been under fire as
an area for improvement or replacement.
Glutaraldehyde is widely known to compromise the normal tissue mechanics of
the aortic valve. However, various pressure fixation techniques have been developed to
help reduce this phenomenon.

First generation porcine BHVs were fixed under a

backpressure of 80 mmHg, similar to natural diastole. This fixed the valve in the closed
position, which yielded a visually pleasing, smooth cusp shape and proper coaptation.
However, high-pressure fixed BHVs were soon found to have inferior biomechanics and
durability due to excessively rigid cusps. The high-pressure fixation technique was found
to extend macroscopic collagen corrugations as well as microscopic crimp, therefore
locking collagen fibers into an elongated position and greatly reducing cusp flexibility.
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Following generations have employed low-pressure and zero-pressure fixation techniques
that possess improved tissue biomechanics and overall long-term durability [71].
Despite fixation process improvements, collagen microarchitecture still becomes
locked into its initial fixed configuration, preventing the dynamic ECM restructuring that
accompanies normal valve function. This results in stiffer, less compliant tissue that is
more prone to tissue buckling and other localized mechanical stresses [5].

Tissue

mechanics are further skewed by the loss of elastin and GAGs, other important cusp
components that contribute to normal function. These molecules do not possess the
amine functionalities necessary for crosslinking by glutaraldehyde and are lost during
preparation, storage, and function. GAG loss stems primarily from the spongiosa layer,
which normally functions to reduce internal shear stresses, absorb compressive stresses,
and prevent tissue buckling [15,18,19,25,31,75]. The loss of these important functional
molecules and the resulting changes in tissue mechanics may contribute to structural
deterioration, the foremost cause of BHV failure.
Glutaraldehyde fixation has also been linked with calcification, the other major
means of BHV failure, as was previously discussed in section 1.4.4.3.2.

Although

mechanical damage has a well-known synergy with calcification, glutaraldehyde fixation
has also been directly linked to calcification through various other pathways [5,62,78].
Devitalization and other cell alterations result in the formation of cell debris, which
function as nucleation sites for mineralization [5,6].

Glutaraldehyde is thought to

stabilize these structures, although some studies using high concentrations of
glutaraldehyde has shown shielding effects against calcification [78]. Residual unreacted
glutaraldehyde has also been implicated in calcification and the use of amine
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neutralization treatments have shown to nullify mineralization [6]. Many other anticalcification strategies have been researched and were lightly discussed in section 1.4.4.4.
However, a more in depth look at one approach, alternative fixation methods, is provided
in section 1.8.
A

B

Figure 23. [A] Free glutaraldehyde molecule and its polymeric form after aqueous
uptake [B] Simplified example of crosslinking between two collagen molecules using
glutaraldehyde (Both figures adapted from [103]).

1.7.

Alternative Fixation Methods

The perceived contributions of glutaraldehyde treatment to BHV failure have lead
to a search for suitable alternatives. Alterations to glutaraldehyde fixation methods as
well as replacements have been pursued in recent years. Modifications have ranged from
changes as simple as using higher concentrations to more involved strategies that reduce
tissue reactivity, block residual aldehyde groups, or incorporate into the crosslinks
[78,104]. Some non-glutaraldehyde tissue fixatives that have been investigated include:
epoxy compounds, such as triglycidalamine [105]; carbodiimides [103,114-120];
acylazides [103]; poly-glycidyl ethers [106]; reuterin [107]; genipin [108]; glycerol
[103]; sodium metaperiodate [88]; diisocyanates [103]; and dye-mediated photooxidation
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[109-112]. Many of these fixatives have yielded promising results through preliminary
testing, but there has been minimal conversion into clinical use.
The primary focus of many studies involving these new chemistries has been on
the reduction of calcification, though there are additional benefits that may also
accompany the nature of this strategy. Possible benefits include: potential enhancement
to tissue stability, improved biomechanics, and reduction of fixative toxicity. However,
the use of entirely new fixation chemistries also risks providing inadequate tissue
durability as well as stimulating unknown host responses. BHVs crosslinked by dyemediated photooxidation and carbodiimides have progressed to clinical trials; however,
neither has yet further advanced to regular clinical use.

Both of these particularly

promising compounds do not become incorporated into the tissue, but merely catalyze the
formation of covalent bonds within the tissue. This particular characteristic all but
ensures reduced toxicity and early results have demonstrated reduced calcification in
tissues crosslinked by each treatment [109-111,116-119].

The use of these new

crosslinking methods, along with proper valve construction, may improve the average
lifetime of BHVs representing the next evolution in their design.

1.7.1. Dye-mediated photooxidation
Fixation processes using dye-mediated photooxidation are fairly simple and
include incubation in the photooxidative dye of interest, followed by exposure to specific
wavelengths of light in an aerobic environment. However, the mechanisms behind this
method of crosslink formation are not fully understood [111-112]. After light absorption
by the dye, excitation initiates the crosslinking response that is theorized to include
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reactions involving singlet oxygen and amino acids with the light-excited dye [112].
Methylene blue and methylene green are two dyes that have been investigated for use in
BHV fixation [109-112]. Investigation of multiple dyes has also been augmented by
exploration of differing wavelengths of light as well as varying lengths of exposure [112].
In addition to demonstrating resistance to enzymatic degradation and
calcification, tissues crosslinked using dye-mediated photooxidation have also exhibited
low immunogenicity, non-cytotoxicity and seemingly improved physical properties [109112]. One particular fixation method, PhotoFix®, progressed to clinical trials but was cut
short due to excessive regurgitation prior to two years. However, upon explantation,
valves consistently exhibited signs of failure due to improper design while tissue
performance seemed to be satisfactory [113]. Nonetheless, this has been a setback for the
advancement of PhotoFix® and other alternative fixation chemistries; as the previously
mentioned study suggests, current testing methods may be inadequate to properly predict
clinical performance.

1.7.2. Carbodiimide Fixation
Water-soluble carbodiimides have also attracted a great deal of interest for use in
alternative fixation methods. A popular pair of carbodiimide crosslinkers that have been
investigated for use in BHV tissue fixation are 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-hydroxysuccinimide (NHS). As mentioned previously, these
reagents react to produce zero-length bonds within the tissue. This refers to the fact that
neither EDC nor NHS remains in the bond after crosslink formation, but merely catalyzes
the formation by utilizing available amino acid side groups [103,114-120].
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Collagen crosslinking is initiated when EDC activates carboxyl groups on aspartic
and glutamic acid, which then reacts with NHS to form a stable intermediate. NHS
allows for increased crosslinking yield and facilitates reaction with nucleophiles, such as
primary amines on lysine and hydroxylysine of collagen [114,115].

There is also

evidence that these activated carboxyl groups can form ester crosslinks with hydroxyl
groups, furthermore, in sufficient quantity to significantly affect tissue mechanics [114].
Tissue mechanics is a concern with carbodiimide crosslinked tissue as the zerolength bonds produced by crosslinks have been stated to yield undesirable collagen
stiffness [116]. As such, some groups have investigated the incorporation of diamine
spacer molecules into carbodiimide crosslinks that create “lengthened” bonds. These
strategies aim to both enhance tissue stability and reduce stiffness, although, the majority
of these alternative fixation studies have primarily focused on the reduction of
calcification [116-119].
The amide bonds formed by EDC/NHS fixation are more stable than the Schiffbase bonds created by glutaraldehyde fixation, and it is theorized that carbodiimide
crosslinking may offer superior collagen stability [117]. This theory is also suggested
through a hypothesis submitted by Weadock et al., which proposes that improved
stability is afforded due to the formation of a larger number of crosslinks using
EDC/NHS treatment [115,121].

In addition to the collagen stability afforded by

EDC/NHS fixation, GAGs can also be crosslinked through carbodiimide chemistry due to
the high amount of available carboxyl groups situated on GAG molecules (Figure 3).
The preservation of GAGs may further protect collagen sterically through the blockage of
cleavage sites that are vulnerable to enzymatic attack [115]. GAGs may also improve

63

tissue stability through the improvement of tissue and valve biomechanics. Even slight
improvements could delay the onset of fatigue damage and, as a result, slow structural
degradation.

Also, since EDC/NHS crosslinked tissues have exhibited resistance to

calcification, carbodiimide crosslinking becomes an even more attractive alternative to
glutaraldehyde fixation for improved BHV durability [116-119].

Figure 24. Representation of carbodiimide crosslinking in the presence of NHS [120].

1.8.

GAG Loss in BHVs

Glutaraldehyde is currently the standard treatment used for the preservation of
tissue structure. Although it is effective at collagen stabilization, it fails to preserve both
GAGs and elastin because they lack the amine functionalities necessary to be crosslinked.
The loss of GAGs has been demonstrated to occur during preparation, storage, cyclic
fatigue, and implantation [15,18,19,30,75]. The effects of this GAG loss on the ultimate
failure of BHVs is unclear, but has been theorized to contribute to both major modes of
malfunction, including calcification and structural damage.
Versican and HA aggregates have been demonstrated as the primary contributors
to overall GAG loss. This is most likely due to steric hindrance from side GAG chains
preventing the crosslinking of protein cores within these aggregates.

Also, these

molecules are for the most part unbound, especially in the spongiosa, leading to loss by
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leaching. This is opposite smaller PGs, like decorin, which are better preserved. The
protein cores of smaller PGs are less obstructed by GAG chains and are therefore more
open to crosslinking [19]. However, given the function of these small PGs, it is unlikely
that they would have any beneficial effect on the lifeless tissues of BHVs [17,19, 21].
The role of GAG loss in structural damage is thought to be particularly
significant and starts with detrimental changes to tissue biomechanics. This primarily
concerns the loss of GAGs associated with the PG versican within the spongiosa. The
loss of the primary component of this important tissue layer increases internal shear
stresses and has been shown to cause increased flexural rigidity [18]. The increased
flexural stiffness also brings about increased compressive stresses during flexure, and
GAG depleted tissues have been shown to be more prone to tissue buckling [31].
Versican expression has been demonstrated to be highest in the spongiosa, and losses of
versican and HA aggregates have been shown to be the primary contributors to overall
GAG loss [19,131]. This further supports the fact that versican aggregate loss from the
spongiosa is the primary contributor to the deterioration of valve biomechanics.
The loss of GAGs may also contribute to calcification, although indirectly, as
areas of high flexural stresses have also been demonstrated to generally coincide with
increased calcification [124,127]. More direct relationships are also possible as versican
is associated closely with elastin networks and versican expression has been verified to
be second highest in the ventricularis [19,131]. Unlike collagen, purified elastin has been
shown to calcify heavily, regardless of crosslinking; while versican binding, under
normal conditions, has been implicated as an inhibitor to elastin calcification [19]. GAGs
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may also prevent hydroxyapatite nucleation through the chelating of calcium, which
inhibits reaction with extracelluar phosphate [75].

1.9.

GAG Preservation Strategies

As mentioned in the previous section, it has been demonstrated that GAGs are lost
from BHV tissues during preparation, fatigue, implantation, and storage [15,18,19,30,75].
GAGs are thought to be vital to the proper biomechanical function, and discussion of
their structure and function has been laid out in sections 1.1.1.2.3, 1.1.1.3.3, 1.2, 1.5, and
1.8. They reside primarily within the central spongiosa layer of cusp tissue and their loss
has been attributed to increases in tissue buckling depth as well as flexural rigidity
[18,31]. These changes may cause additional undue stresses on BHV tissue, which
damage collagen fibers and ultimately lead to BHV failure.
Our lab has attempted to improve GAG preservation using various crosslinking
strategies. Sodium metaperiodate and carbodiimide crosslinking using EDC/NHS have
exhibited improved GAG stabilization when coupled with glutaraldehyde fixation
[30,31,88,132,133].

Sodium periodate has been evaluated without the addition of

glutaraldehyde, but was found to provide insufficient collagen stability [88]. Regardless,
it has been shown that none of these fixation chemistries were adequate to fully preserve
GAGs when subject to enzymatic degradation [30,88,132,133].

Therefore, it was

hypothesized that a GAG degrading enzyme inhibitor needs to be employed in order to
provide full protection against GAG loss.
Neomycin trisulfate, a hyaluronidase inhibitor, has an ideal structure for this
function and possesses multiple amine functionalities that allow it to be incorporated into
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BHV tissue by using numerous crosslinking strategies.

Neomycin prevents the

enzymatic digestion of GAGs both by the blocking of active cleavage sites as well as
through binding and interacting with hyaluronidase. The presence of hydrophilic groups
in combination with lipophilic residues facilitates this binding and allows neomycin to
sterically interfere with the active site of hyaluronidase, subsequently causing a
conformational change that renders the enzyme ineffective [31,133].
Neomycin has been demonstrated to supplement GAG protection in cusp tissue
when subjected to both cyclic mechanical fatigue and storage. This was demonstrated in
tissues crosslinked with both EDC/NHS and glutaraldehyde as well as in tissue fixed
using glutaraldehyde alone [30,UD*].

Reduced tissue buckling was found in these

tissues, providing further evidence of the importance of GAG preservation [31]. In
addition to improved GAG stability, collagen and elastin were also further stabilized by
neomycin through unidentified mechanisms [30,UD]. Altogether, the incorporation of
neomycin into BHV tissues helps prevent GAG loss, which may contribute to better
overall ECM stability. This may increase BHV durability by delaying the mechanisms
that lead to structural damage and ultimately BHV failure. (*UD=unpublished data)

Figure 25. Structure of neomycin trisulfate (www.sigmaaldrich.com).
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2.

RESEARCH RATIONALE
2.1.

Overview

Lack of long-term durability remains the primary concern for BHVs with the
majority failing within 12-15 years after implantation into adults. Although this may be
adequate for many patients, BHV implantation can be contraindicated in younger
individuals in order to avoid reoperation. Even in elder recipients, valve dysfunction can
still cause death or reoperation that could be avoided with increased BHV durability.
Therefore, investigation into methods for increased BHV durability is warranted in order
to both widen the patient demographic as well as improve the quality of life for BHV
recipients.
Improving BHV durability requires prevention of the two foremost causes of
failure, calcification and non-calcific structural degradation. Glutaraldehyde crosslinking
has been implicated as a contributor to both of these phenomena and has long been a
target of improvement or replacement. Investigation into alternative fixation methods has
yielded many options, many of which have demonstrated increased resistance to
calcification. However, even with a fixation method that offers 100% reduction of
mineralization, structural damage from mechanical sources would still lead to failure.
This requires the development of fixation strategies that not only reduce calcification, but
also resist the accumulation of structural damage.
The accumulation of non-calcific damage is highly dependent on cusp mechanics,
and even minor biomechanical alterations can have profound implications on the fatigue
life of BHVs. This stems from the lack of tissue repair mechanisms that leads to a
cumulative effect for all incurred mechanical damage.
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Important biomechanical

molecules, GAGs, are not crosslinked by glutaraldehyde fixation and are consequently
lost during implantation, storage, and cyclic mechanical fatigue. The increased flexural
rigidity and tissue buckling that results from GAG loss may have direct repercussions on
collagen integrity, which leads to cusp tears that cause valve insufficiency and failure.
Carbodiimide crosslinking using EDC and NHS is a particularly promising
alternative fixation treatment. This method of crosslinking is capable of reacting with
carboxyl groups as well as amines, enabling the crosslinking of both GAGs and collagen.
This difference in crosslinking chemistry also causes changes to the ECM
microarchitecture that may affect mechanical properties. As a result, improvements to
tissue mechanics may occur through increased GAG preservation along with differing
crosslink architecture.

Additionally, tissues crosslinked using EDC and NHS have

demonstrated improved resistance to calcification using in vivo models.
The crosslinking of GAGs alone may not be sufficient to preserve them, since
they are still be prone to loss through enzymatic degradation. The use of neomycin, a
hyaluronidase inhibitor, additionally protects GAGs by preventing enzymatic cleavage.
Integration of neomycin into tissues is facilitated by the presence of multiple amine
groups that permit integration into carbodiimide-initiated crosslinks.
We propose that the addition of neomycin into EDC/NHS fixation will
demonstrate superior GAG stability while also exhibiting reduced calcification when
compared to glutaraldehyde crosslinked tissue. Cusp tissue will be treated as such and
assessed for general tissue stability as well as for the ability to resist GAG loss from all
sources.

Basic mechanical testing will also follow in order to obtain initial

characterization on the effects of this crosslinking method on tissue mechanics.
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2.2.

Specific Research Aims

2.2.1. Aim I: What is the optimal concentration of neomycin needed to improve
GAG preservation during in vitro degradation and storage?

Hypothesis: GAGs may be stabilized through EDC crosslinking due to bonding of
available carboxyl groups to free amine groups on collagen. The presence of bound
neomycin may further stabilize GAGs through the prevention of enzymatic degradation.
Experimental Plan:

Porcine aortic valve cusps will be treated using various

concentrations of neomycin and then subjected to enzymatic degradation.

Tissues

crosslinked using the optimal treatment will be compared to EDC treated tissue with an
inert amine functional molecule added in order to verify the specific contribution of
neomycin to GAG preservation.

GAG stability will be measured after enzymatic

degradation and storage. Tissue GAG content will be quantified using hexosamine and
DMMB assays, in addition to being visually verified via histology.

2.2.2. Aim II: Does neomycin further enhance EDC crosslinking of collagen and
elastin in porcine aortic valve cusp tissue?

Hypothesis: The available amine functionalities on neomycin may enable interaction
with EDC/NHS during crosslinking. The incorporation of neomycin into crosslinks may
affect the stability of collagen and elastin.
Experimental Plan: NEN treated porcine aortic valve cusps will undergo collagenase and
elastase treatment. Resistance to enzymatic degradation will be used as an indicator of
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elastin and collagen stability. Differential scanning calorimetry will also be used to
detect any changes in the collagen denaturation temperature of the tissue. Data will be
compared to that of a GLUT control as an indicator for baseline performance.

2.2.3. Aim III: Does neomycin used with EDC crosslinking demonstrate improved
in vivo performance?

Hypothesis: The physical crosslinking along with neomycin protection in the NEN
treatment may prevent the loss of GAGs due to in vivo degradation. Calcification may
also be reduced for the NEN group due to the lack of glutaraldehyde crosslinks.
Experimental Plan: Rat subdermal implantation will be used to assess the performance of
various crosslinking strategies. Hexosamine assay will be used to quantify the remaining
GAGs after implantation, while atomic absorption spectroscopy will be used to quantify
mineralization. Results will be also verified visually via histology.

2.2.4. Aim IV: Does neomycin used with EDC crosslinking affect the stiffness and
extensibility of porcine aortic valve cusp tissue?

Hypothesis: The unique crosslinks formed within the NEN treated groups may cause the
cusp tissue to exhibit different levels of stiffness and extensibility when compared to
fresh tissue and GLUT fixed tissue.
Experimental Plan:

Uniaxial tensile testing will be used to analyze stress-strain

relationships for all groups in both the radial and circumferential directions.
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3.

MATERIALS AND METHODS
3.1.

Materials

Ammonium acetate, calcium chloride, chondroitinase ABC from Proteus vulgaris,
collagenase type VII from Clostridium histolyticum, 1,9–dimethylmethylene blue
(DMMB), (D+) glucosamine HCl, hyaluronidase type IV-S from bovine testes,
chondroitin sulfate C sodium salt, and neomycin trisulfate hydrate were all purchased
from Sigma-Aldrich Corp (St. Louis, MO).

Acetyl acetone, TRIS buffer, glycine,

hydrochloric acid, sodium azide, p-dimethylaminobenzaldehyde, and 4-(2-hydroxyethyl)1-piperazineethanesulfonic acid (HEPES) were purchase from Fisher Scientific (Fair
Lawn, NJ). Sodium Chloride, sodium carbonate, and 1,6-hexane diamine was purchased
from Acros Organics (Morris Plains, NJ). Elastase from porcine pancreas (135 U/mg)
was purchased from Elastin Products Company (Owensville, MO).

EM Grade

Glutaraldehyde- 8% wt. in H2O was purchased from Polysciences Inc. (Warrington, PA).
2-(N-morpholino) ethanesulfonic acid (MES) and Ultra II ultra pure hydrochloric acid
was purchased from J.T Baker (Phillipsburg, NJ). n-hydroxysulfosuccinimide (NHS)
was obtained from Pierce Biotech (Rockford, IL). Lanthanum(III) oxide was purchased
from Alfa Aesar (Ward Hill, MA).

10% buffered formalin, 1-ethyl-3-(3-

dimethylaminopropyl) carbodiimide (EDC), and isopropyl alcohol were purchased from
VWR International (West Chester, PA). Sodium Phosphate (dibasic) was purchased
from EMD Chemicals (Gibbstown, NJ). Porcine aortic valves from Snow Creek Meat
Processing (Seneca, SC).
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3.2.

Methods

3.2.1. Porcine Aortic Valve Acquirement
Fresh porcine aortic valves were harvested on site at a local slaughterhouse, Snow
Creek Meat Processing (Seneca, SC). Valves were excised immediately upon animal
death and were removed by cutting just below the aortic cusps and just above the aortic
sinuses. The valves were transported on ice back to the laboratory where the valves were
rinsed thoroughly using physiological saline. The valve leaflets were then separated and
excess muscle tissue, aortic wall, and fat was removed leaving only the leaflet tissue and
approximately 0.5 cm to 1 cm of aortic wall connected beyond leaflet to wall interface.
After rinsing and trimming, all tissue was subject to immediate fixation.

3.2.2. Tissue Fixation Methods
For all fixation steps, 33 mL of fluid was used per valve cusp. Fixation processes
were carried out at room temperature within 4 hours of harvesting and were as follows:

CONTROL GROUPS:
GLUT: Tissue was placed in 0.6% glutaraldehyde in 50 mM HEPES buffered saline (pH
7.4) for 24 hours. Solution was then replaced with 0.2% glutaraldehyde in 50 mM
HEPES buffered saline (pH 7.4) for another 6 days.

EDC: Tissue was placed in 30 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC) and 6 mM N-hydroxysuccinimide (NHS) in 50 mM MES buffered saline (pH 5.5)
for 24 hours. Valves were then placed in 10% formalin (pH 7.4) for another 6 days.
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EXPERIMENTAL GROUPS:
NEN: Tissue was placed in 0.5 mM neomycin trisulfate in 50 mM MES buffered saline
(pH 7.4) under constant orbital shaking for 1 hour. After incubation in neomycin,
fixation proceeded identical to the EDC fixation method.

NOTE:
•

NEN refers to valves that underwent fixation as above.

If a concentration is

specified, this refers to a change in neomycin trisulfate concentration only. If left
unspecified, 0.5 mM neomycin trisulfate concentration should be assumed.

EXPERIMENT SPECIFIC CONTROL GROUPS:
HEX: Tissue was placed in a 1.5 mM solution of 1,6-hexanediamine in 50 mM MES
buffered saline (pH 5.5) under constant orbital shaking for 1 hour.

Fixation then

proceeded identical to the EDC fixation method. ***HEX was used to provide a control
for neomycin’s amine functionalities and their contribution to ECM preservation.***

NEX: Tissue was placed in 0.5 mM neomycin trisulfate in 50 mM MES buffered saline
(pH 7.4) under constant orbital shaking for 1 hour. After incubation in neomycin, tissue
was placed in 30 mM (EDC) and 6 mM (NHS) in 50 mM MES buffered saline (pH 5.5)
for 24 hours. Tissue was then stored in a solution of 80% 50 mM HEPES buffered saline
(pH 7.4) and 20% isopropyl alcohol.

***NEX was used to provide a control for

formaldehyde and its contribution to collagen stability.***
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NOTES:
•

Valves not used immediately were stored in their final fixation solution until needed.

•

After fixation, immediately prior to all experiments, aortic wall tissue was separated
from leaflet tissue and discarded.

3.2.3. Enzymatic Degradation of GAGs
GAG degrading enzyme solution (GAGase): 5 U/mL hyaluronidase and 0.1 U/mL
chondroitinase in 100 mM ammonium acetate buffer (AAB, pH 7.0). Leaflets were
thoroughly washed in 100 mM AAB for 3 changes of 5 minutes each. Leaflets were then
approximately cut into two equal halves and briefly blotted dry. Half of each cusp was
put into 1.2 mL of GAGase, while the other half was put into 1.2 mL of AAB as a
control. Both groups were incubated under high agitation at 37°C for 24 hours. After
incubation, leaflets were removed from solution and thoroughly rinsed in distilled water.
All solutions were saved for both DMMB and hexosamine analysis, while the tissue was
blotted dry, frozen, and saved for hexosamine analysis (Sections 3.2.4 and 3.2.5). (n=6)

3.2.4. GAG Quantification: Hexosamine Assay
Tissues were lyophilized, weighed, and then acid hydrolyzed in 2 mL of 6 M HCl
for 20 hours at 95ºC. Resulting solutions were then dried under nitrogen gas and resuspended in 2 mL of 1 M NaCl. These were reacted with 2 mL of 3% acetylacetone in
1.25 M sodium carbonate solution for 1 hour at 95°C and let cool to room temperature.
The following were then added to each sample followed by vortex mixing: 4 mL of 100%
ethanol and 2 mL of Ehrlich’s reagent (.18 M p-diemethyl-aminobenzaldehyde, 50%

75

ethanol in 3.0 N HCl). Samples were allowed to sit at room temperature for 45 minutes to
allow sufficient reaction time. The resulting color product indicative of hexosamine
quantities was read for absorbance at 540nm. A set of D (+) glucosamine solutions (1200µg) was used to produce a standard curve, and all values were normalized to their
respective dry tissue weights. It was previously determined that resulting hexosamine
values include ~90µg /10mg of non-GAG related hexosamines. Thus, this assay was
performed as it has been previously, and this value was subtracted from all data
[18,30,31,131,132].

Spectrophotometery

was

performed

using

the

µquant

spectrophotometer (BIO-TEK Instruments, Winooski, VT).
In addition to tissues, hexosamine was also performed on the resulting lysate
solutions obtained during the enzymatic degradation of GAGs, per section 3.2.3.
Methods were identical with only one change; the lyophilized solution was acid
hydrolyzed using only 1 mL of 2 M HCl. (n=6)

3.2.5. GAG Quantification: DMMB Assay
DMMB assay was performed, as it has been previously, in order to quantify
sulfated GAGs leached from tissue into the corresponding enzyme or buffer solution as
outlined in section 3.2.3. The following were pipetted into the individual wells of a 96
well plate: 20µL of each sample, 30 µL of PBE buffer (100 mM Na2HPO4), and 200 µL
of DMMB reagent (40mM NaCl, 40mM glycine, 46 µM DMMB, pH 3.0). Chondroitin
sulfate solutions (0 - 1.25µg) were used to produce a standard curve. The resulting
purple-like color change was indicative of sulfated GAG presence and was read for
absorbance at 525 nm. This is done immediately to avoid degradation of the unstable
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DMMB dye-GAG complex [30,31,133,134]. Spectrophotometery was performed with
the µquant spectrophotometer (BIO-TEK Instruments, Winooski, VT). (n=6)

3.2.6. Collagen and Elastin Stability
Collagen and elastin stability is assessed using resistance of leaflet tissue to
enzymatic degradation. Leaflets were cut in half, rinsed in distilled water, blotted dry,
and then frozen at -80°C. Samples were then lyophilized for 24 hours and weighed prior
to treatment with either porcine pancreatic elastase or Type VII collagenase, as described
previously. Six half leaflets were placed in either 1.2 mL of 5.0 U/ml elastase (100 mM
Tris buffer, 1 mM CaCl2, .02% NaN3) or 1.2 mL of 75 U/ml collagenase (50 mM CaCl2,
.02% NaN3, pH 8.0). Elastase samples were incubated for 24 hours while collagenase
samples were subject to 48 hours. Both groups were carried out at 37ºC under constant
shaking at 650 RPM. Samples were then removed from solution, rinsed, blotted dry, and
frozen at -80ºC. They were then lyophilized and the final dry weight was taken. This
weight along with initial dry weight was used to determine the percent weight loss. (n=6)

3.2.7. Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was used to determine the collagen
denaturation temperatures (Td), previously described as the temperature at the
endothermic peak [135]. Small (3 – 10 mg) samples were cut from generally the same
region of different cusps, immediately adjacent to the nodule of arantius. These samples
were carefully cut to size to enable them to lie flat within the DSC pans. Samples were
then weighed and briefly blotted dry before encasing them within hermetically sealed
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DSC pans. In the interest of conserving time, a pilot experiment was run with each group
to determine an approximate value for Td. In this pilot run, samples were heated from
25ºC to 105ºC at 2.5ºC/min. All subsequent runs were heated at 10ºC/min. until a point
20ºC before the pilot run Td, at which point a one-minute isothermal was held before
proceeding to 105ºC at 2.5ºC/min.

The collagen denaturation temperature that was

recorded was taken from the most extreme value within the endothermic peak. All
samples were run on DSC 2910 (TA Instruments, New Castle DE). (n=4)

3.2.8. Neomycin Optimization for NEN treatment
NEN fixation was performed using various concentrations of neomycin trisulfate
from 0.05 mM to 2 mM. EDC and GLUT groups were used as controls. All tissues were
then subjected to GAG-degrading enzymes, as outlined in section 3.2.3. GAG stability
was assessed by hexosamine assay and DMMB analysis (Sections 3.2.4 and 3.2.5). (n=6)

3.2.9. Histological Assessment
Radial cusp cross-sections were taken from the cusp center and stored in 10%
buffered formalin (pH 7.4) until use. Samples were then embedded in paraffin wax and
sectioned for light microscopy analysis. For GAG analysis, alcian blue staining with a
nuclear fast red counterstain was used, where blue staining is indicative of GAG
presence. For calcium analysis, Dahl’s alizarin red staining was used with a light green
counterstain, where red staining is indicative of calcification. Digital photographs were
taken with a Zeiss Axioskop 2 Plus (Carl Zeiss MicroImaging, Inc., Thornwood, NY) in
conjunction with SPOT Advanced software.
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3.2.10. Uniaxial Tensile Testing
For uniaxial tensile testing, the MTS Synergie 100 (MTS Systems, Eden Prairie,
MN) was used with a 10 N load cell along with Testworks 4 software. Sections were cut
from whole leaflets, approximately 4 mm wide using a rectangular tissue stamp. Sections
were taken from the center of the cusps in both the radial and circumferential directions
and were only cut immediately before they were to be run. The samples were then placed
within custom grips that were lined with fine sandpaper to protect the tissue from tearing.
The tissue was then preloaded to a small tension (0.01 N - radial, 0.1 N – circumferential)
and the tissue’s dimensions were taken. The tissue was then stretched at a constant rate
of 12.5 mm/min and the resulting stress-strain curve was used for analysis. (n=6)

3.2.11.

Rat Subdermal Implantation

All tissues were rinsed thoroughly through three changes of sterile saline for 30
minutes each and remained in sterile saline until implantation. Male juvenile SpragueDawley rats (35-40g, Harlan Laboratories, Indianapolis, IN) were anesthetized by
inhalation of 3% isoflurane gas. Two incisions were made on the dorsal side of each rat,
one on each side of the sagittal plane, and the skin was carefully lifted up to form a
pocket. Cusps were blotted dry and positioned in the pockets to lie as flat as possible.
Incisions were closed using surgical staples and tissues were retrieved at three weeks.
Half of each cusp was used for hexosamine analysis (section 3.2.4) and the other half was
analyzed for mineral content (section 3.2.12). Small middle sections were taken for
histology and immediately immersed in 10% buffered formalin. All other samples were
immediately put on dry ice and frozen at -80ºC as soon as possible. (n=10)
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3.2.12.

Calcium and Phosphorus Analysis

Sample Preparation: First, samples were lyophilized for 24 hours and then weighed.
Tissues were then acid hydrolyzed in 2 mL of 6N Ultrex II HCl for 20 hours at 95ºC.
Samples were then dried under nitrogen and resuspended in 1 mL of 0.01 N Ultrex II
HCl. Only small amounts of the sample are used for both calcium and phosphorus
assays. Dilution is used to bring samples near the range of the standard curve for each
analysis.

Calcium and Phosphorus Analysis: A small amount of each sample was used to make a
100x dilution in distilled water and Clemson University faculty performed calcium and
phosphorus analysis at the Clemson University Agricultural Service Laboratory.
Analysis was performed using the Spectro Arcos ICP Spectrometer (SPECTRO
Analytical Instruments, Kleve, Germany). Dilution ratios were used to determine the
total mineral content of the sample and values were normalized to the dry tissue weight.

3.2.13. Storage Studies
The GAG content of leaflets was analyzed using hexosamine assay (section 3.2.4)
after two, four, and six months of storage at room temperature. All valves were stored in
the respective final solutions that were used in their fixation process. Short-term storage
effects on resistance to enzymatic digestion of GAGs were also tested. (n=6)
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3.2.14 Statistical Analysis
All results are expressed as the mean ± standard error of the mean (SEM). All
statistical analysis was performed using single factor analysis of variance (ANOVA).
Differences between the means were determined using least-significant difference with a
significance level of α = 0.05.
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4.
4.1.

RESULTS

Neomycin Optimization for NEN Treatment

To determine the most effective concentration of neomycin to use with the NEN
treatment, porcine aortic valve leaflets were crosslinked by NEN using various
concentrations of neomycin ranging from 0.05 mM to 2 mM. These tissues were then
assessed for resistance to GAG degrading enzymes and compared to performance by
EDC and GLUT groups. Hexosamine and DMMB analysis were performed after enzyme
digestion was completed. It is important to note that the hexosamine assay measures
non-sulfated and sulfated GAGs, while the DMMB assay is only capable of quantifying
sulfated GAGs.
Hexosamines remaining in the tissue were measured and all concentrations of
neomycin above 0.5 mM in the NEN groups retained high amounts of GAGs within the
tissues (Figure 4.1). Low neomycin concentration NEN groups (0.05 mM – 0.25 mM)
exhibited significantly lower GAG levels for both buffer and enzyme treatments with no
significant difference between the two. GLUT offered the least resistance to GAG loss
with only 79.48 + 17.09 µg GAGs / 10 mg dry tissue remaining after enzymatic digestion
compared with 141.54 + 11.14 µg GAGs / 10 mg dry tissue remaining after storage in
buffer.

All GAG digested NEN groups with higher than a 0.5 mM neomycin

concentration yielded significantly higher tissue GAG contents than both GLUT and
EDC (p<0.03). EDC offered some protection against enzymatic attack preserving an
average of 40.68 + 30.82 µg GAGs / 10 mg dry tissue more than GLUT (p=0.03). The
0.5 mM neomycin was the optimal concentration to fully preserve GAGs, exhibiting an
average of 104.4 + 30.41 µg more GAGs / 10 mg dry tissue than GLUT (p=0.001).
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Figure 4.1: Quantification of GAGs remaining in the tissue after GAG digestion by
hexosamine assay. “Red star” indicates significant difference between digested and
undigested tissue (p<0.05, n=6 per group).

Hexosamine assay was also performed on the solutions that were used to digest
the tissues (Figure 4.2), and general trends appeared to be the same. No significant
differences were detected in the GAG levels of the buffer solutions between any groups.
The 0.5 mM NEN treatment again seemed to be optimal, losing negligible amounts of
GAGs to enzymatic attack. Differences from both 1 mM and 2 mM NEN groups were
not significant. Significant differences in the amount of GAGs lost between EDC and
low concentration NEN groups (0.05 – 0.25 mM) were not found. This suggests that
such low neomycin concentrations add little GAG protective effect. The EDC group
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seemed to offer some resistance to enzymatic degradation, losing only 10.75 + 4.52 µg
GAGs/10 mg dry tissue. On the other hand, GLUT offered the least protection, losing
69.95 + 4.17 µg GAGs/10 mg dry tissue.

Figure 4.2: Quantification of GAGs lost into solution during GAG digestion by
hexosamine assay. “Red star” indicates significant difference between digested and
undigested tissue (p<0.05, n=6 per group).

DMMB assay was used to further confirm results and was performed on the
solutions. With the exception of the GLUT and 0.5 mM NEN groups, all other tissues
subjected to GAG degrading enzymes lost significantly more sulfated GAGs into solution
than those stored in buffer solution.

This suggests protection against enzymatic

degradation by the 0.5 mM NEN group, considering the small amounts of GAGs lost.
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However, lack of protection is suggested by the GLUT group as the average GAG losses
were significantly higher than 0.5 mM NEN, with 25.3 + 6.55 µg /10 mg dry tissue
(p=0.0015) more sulfated GAGs lost to buffer and 29.27 + 5.94 µg/10 mg dry tissue
(p<0.001) more lost to enzymatic digestion. In agreement with hexosamine assay results,
no significant difference was found between GAGs lost for the low neomycin
concentration group and the EDC group; suggesting again, that such low neomycin
concentrations little GAG protective effect. Once more, the 0.5 mM NEN treatment was
determined to be the most effective at preventing sulfated GAG loss, losing negligible
amounts on both accounts. The 0.5 mM group also preserved 7.52 + 4.86 µg/10 mg
(p=0.051) more sulfated GAGs than the 2 mM NEN, group when subjected to GAGase.

Figure 4.3: Quantification of sulfated GAGs lost into solution during GAG digestion by
DMMB assay. “Red star” indicates significant difference between digested and
undigested tissue (p<0.05, n=6 per group).
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The combined results from hexosamine and DMMB assays led to the choice of
0.5 mM neomycin concentration to represent the NEN group for all other
experimentation. The choice of a 0.5 mM neomycin concentration for NEN was further
verifed by histological evaluation. Intense blue staining, indicative of GAGs, was seen
for both GAG-digested and undigested valves in the 0.5 mM NEN group (Figure 4.4).
EDC again seemed to offer some resistance to GAG digestion as lighter blue staining was
seen, while GLUT offered the least resistance and demonstrated almost an entire absence
of blue staining. Alcian blue staining agrees with the values of Figure 4.3, except for the
progressive decreases in blue staining that are present in the undigested tissue pictures.
This is possibly due to excessive time in storage prior to embedding and sectioning, and
may be indicative of resistance to GAG loss in storage.
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Figure 4.4: Histological sections of porcine aortic valve cusps after storage in buffer and
GAGase (Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – Buffer
stored [B] EDC – Buffer stored [C] GLUT – Buffer stored [D] NEN – GAG Digested
[E] EDC – GAG Digested [F] GLUT – GAG Digested
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4.2.

1,6-Hexane Diamine as a Control for Neomycin

Substances with multiple amine functionalities have been commonly used by
certain groups to enhance EDC/NHS crosslinking.

These molecules perform this

function by acting as bridge molecules during crosslink formation that lengthen
carbodiimide-initiated zero-length bonds [116-119]. Neomycin is incorporated to
carbodiimide crosslinks in the same manner and may similarly result in enhanced
EDC/NHS crosslinking. To prove our hypothesis that neomycin, when bound to tissue,
inhibits enzymatic activity and does not just improves EDC crosslinking, we used 1,6
hexane diamine as a control. 1,6-hexane diamine is not an inhibitor of GAGase enzymes,
but provides similar amine functionalities to improve EDC crosslinking.
1,6-hexane diamine has been previously used as an EDC/NHS crosslink coupler
and is incorporated into HEX fixation [117]. Since neomycin has three times the amine
groups per molecule, a triple (1.5 mM) concentration of 1,6-hexane diamine was used to
provide control for amine functionalities.

HEX and NEN were both subjected to

enzymatic degradation and GAG retention and losses were analyzed using hexosamine
assay, DMMB assay and histology.
NEN was shown to overwhelmingly prevent GAG loss better than HEX. There
was no significant GAG loss observed for the digested NEN group, however the HEX
group showed a significant amount of GAG loss. The HEX group showed only 75.3 +
6.02 µg GAGs / 10 mg dry tissue in the GAG digested group compared to 117.44 + 11.14
µg GAGs / 10 mg dry tissue remaining in the buffer stored group (p=0.01). The NEN
group had significantly higher GAG amounts than HEX, with 148.46 + 8.86 µg GAGs /
10 mg dry tissue remaining after GAGase digestion (p<0.001).
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Figure 4.5: GAGs lost into solution after enzymatic digestion per section 3.2.3. [A]
Sulfated GAGs lost for HEX and NEN as measured by DMMB assay. [B] GAGs lost by
HEX and NEN as measured by hexosamine assay. “Red star” indicates significant
difference between digested and undigested tissue (p<0.05, n=6 per group).

Figure 4.6: GAGs remaining in NEN and HEX tissue after digestion per section 3.2.3.
Measured using hexosamine assay. “Red star” indicates significant difference between
digested and undigested tissue (p<0.05, n=6 per group).
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DMMB assay demonstrated that NEN lost only 2.09 + 0.94 µg GAGs / 10 mg dry
tissue to enzymatic degradation accounting for a loss of only 1.47% + 0.66%, while HEX
lost 27.25 + 6.16 µg GAGs / 10 mg dry tissue or a loss of 23.2% + 5.25%. These losses
between NEN and HEX were significantly different (p=0.01). This is supported by
almost identical results from hexosamine assay when performed on the solutions.
However, results for the NEN group exhibited one discrepancy where significantly more
GAGs to enzymatic digestion when compared to buffer, 8.07 + 1.39 µg GAGs / 10 mg
dry tissue compared to 1.78 + 0.63 µg GAGs / 10 mg dry tissue (p=0.02).
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D

Figure 4.7: Histological sections of porcine aortic valve cusps after storage in buffer and
GAGase (Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – Buffer
stored [B] NEN – GAG digested [C] HEX – Buffer stored [D] HEX – GAG Digested
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DMMB demonstrated that both fixation methods lost negligible amounts into
buffer solution. Hexosamine assay performed on the buffer solutions showed higher
amounts of GAG loss, 1.78 + 0.63 µg GAGs / 10 mg dry tissue lost by the NEN group
and 2.92 + 0.47 µg GAGs / 10 mg dry tissue lost by the HEX group which were not
significantly different (p=0.18). As expected, these losses are extremely small and pale
in comparison to those lost by enzymatic degradation. Results obtained from all three of
the performed assays agree and alcian blue staining, as seen in Figure 4.7, visually
supports these trends.

4.3.

GAG Loss During Storage

The effects of valve tissue storage on GAG loss were tested. Prior to storage all
groups demonstrated similar levels of GAGs within the tissue with no significant
differences detected. After two months of storage, only GLUT lost a significant amount
of GAGs (p<0.001). GLUT valves lost an average of 53.59 + 19.52 µg GAGs / 10 mg
dry tissue in the first two months of storage. After four months of storage there was little
change for any groups when compared to data from the two-month storage time point,
with no significant differences detected. After 6 months of storage both GLUT and EDC
received sharp drops in average GAG levels. From 4 to 6 months storage, EDC lost an
astounding 108.06 + 27.19 µg GAGs / 10 mg dry tissue (p=0.005) while GLUT lost
80.23 + 9.82 µg GAGs / 10 mg dry tissue (p<0.001).
Overall, NEN experienced no significant loss after 6 months of storage when
compared to the initial time point, suggesting full protection against GAG loss due to
storage. After 6 months of storage, EDC lost 118.34 + 33.3 µg GAGs / 10 mg dry tissue
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overall, which is equivalent to 76 + 21.4% loss of all tissue GAGs. GLUT experienced
similar catastrophic GAG loss after 6 months of storage, although the leaching of GAGs
in the GLUT group started as soon as 2 months. When compared to the initial time point,
GLUT lost 125.77 + 22.28 µg GAGs / 10 mg dry tissue or 88.9 + 15.7% of all tissue
GAGs. This same loss was seen visually using alcian blue staining where the GLUT
group displayed almost a complete lack of blue stain. Matching hexosamine assay
results, EDC showed light blue staining suggesting partial GAG preservation and the
NEN group demonstrated superior preservation of GAGs after 6 months of storage.

Figure 4.8: GAGs remaining in NEN, EDC, and GLUT tissue after 0, 2, 4, and 6 months
of storage as measured using hexosamine assay.

“Red star” indicates significant

difference between the two groups (p<0.05, n=6 per group).
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The effect of short-term storage on resistance to enzymatic degradation of GAGs
was also tested. Enzymatic digestion was performed on tissue after two months of
storage. The NEN group demonstrated high resistance to GAG degradation losing only
negligible GAG amounts into solution (Figure 4.10) and retaining high amounts in the
tissue (Figure 4.11). The EDC group offered some protection against enzymatic attack,
losing only 5.33 + 1.65 µg GAGs / 10 mg dry tissue. The GLUT group offered the least
resistance to GAG loss from both treatments, losing 8.87 + 0.93 µg GAGs / 10 mg dry
tissue into buffer solution and significantly more, 29.75 + 4.04 µg GAGs / 10 mg dry
tissue to enzymatic attack (p<0.001).

GLUT exhibited the least amount of GAGs

remaining in the tissue, much less than NEN, with 42.87 + µg GAGs / 10 mg dry tissue
less in the buffer group and 68.19 + 15.54 µg GAGs / 10 mg dry tissue less when
subjected to GAGase.
A
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C

Figure 4.9: Histological sections of porcine aortic valve cusps after 6 months of storage
(Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – 6 months of
storage [B] EDC – 6 months of storage [C] GLUT – 6 months of storage
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Figure 4.10: Quantification of sulfated GAGs lost into solution during GAG digestion by
DMMB assay after two months of tissue storage. “Red star” indicates significant
difference between digested and undigested tissue (p<0.05, n=6 per group).

Figure 4.11: Measure of GAGs remaining in the tissue after GAG digestion by
hexosamine assay after two months of storage. “Red star” indicates significant difference
between digested and undigested tissue (p<0.05, n=6 per group).
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4.4.

Resistance to Collagenase

Resistance to collagenase digestion is used as a common measure of collagen
stability within BHV tissues. Tissues were subjected to collagenase digestion as per
section 3.2.6 and % weight loss after treatment was used to assess performance (Figure
4.12). The HEX group was used as a control for similar reasons that were explained in
section 4.2. HEX was used to determine if the amine groups or bridging effects were
responsible for enhanced crosslinking instead of functions specific to neomycin. There
was no significant difference in percent weight lost between GLUT, HEX and NEN
groups which lost 16.86 + 0.94%, 17.16 + 1.66% and 17.9 + 1.82% weight after
treatment, respectively. This suggests similar collagen stability between these 3 groups,
but all of these groups exhibited significantly lower weight loss than the EDC group
(p<0.013). The NEN group lost 5 + 2.74 % less weight than the EDC group (p=0.001).
Comparatively, the HEX group also lost 5.75 + 2.58% less weight than the EDC group
(p=0.013).

This suggests that neomycin enhances collagen stability in EDC/NHS

crosslinked tissue. However, considering that the HEX group also experienced similar
improvements, this suggests that effects of amine bridging enhance the collagen stability
of EDC/NHS crosslinked tissue instead of functions specific to neomycin.

4.5.

Resistance to Elastase

Resistance to elastase was used as a measure of elastin stability as per section
3.2.6 and % weight loss was used to assess performance (Figure 4.13). The HEX group
was used as a control for the same reasons described in sections 4.2 and 4.4 above. The
NEN and GLUT groups had statistically insignificant differences in percent weight loss
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at 26.69 + 0.68% and 27.36 + 0.62%, respectively. The NEN group exhibited 5.72 +
1.78 less percent weight loss than EDC (p=0.002), suggesting that neomycin improves
the elastin stability of EDC/NHS crosslinked tissue. Also, given that NEN demonstrated
3.81 + 1.83 less percent weight loss than HEX, this suggests that the improved stability is
due to functions specific to neomycin and not due to effects from amine coupling.

Figure 4.12: Results of collagenase digestion per section 3.2.6 expressed as % weight
loss. “Red Star” indicates significant difference from EDC (p<0.05, n=6 per group).

Figure 4.13: Results of elastase digestion per section 3.2.6 expressed as % weight loss.
“Red Star” indicates significant difference from EDC, “Green Star” indicates significant
differences from HEX (p<0.05, n=6 per group).
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4.6.

Differential Scanning Calorimetry (DSC)

The collagen denaturation temperature (Td) for various tissue groups was assessed
as discussed in section 3.2.7.

All groups exhibited a sufficiently high degree of

crosslinking as the Td for EDC and NEN were significantly higher than that of GLUT
(p<0.001). The Td of GLUT was only measured to be 86.59 + 0.56 °C, while EDC and
NEN were measured as 92.83 + 0.36 °C and 93.6 + 0.38 °C, respectively (Figure 4.14).
The insignificant difference between the measured Td’s for the EDC and NEN groups
suggests that neomycin has no affect on the degree of crosslinking for EDC/NHS fixed
cusp tissue. Examples of DSC curves that were obtained are displayed in Figure 4.15, the
endothermic peaks are highlighted and the Td was taken at the point of minimum value
within this peak. Visual overview of these DSC curves, demonstrates the similarities in
collagen thermal stability between EDC and NEN groups.

Figure 4.14: Collagen denaturation temperatures as measured by differential scanning
calorimetry (DSC). “Red Star” signifies significant difference when compared to GLUT.
(p<0.05, n=4 per group).
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Figure 4.15: Overlay of example DSC curves for each tissue group. Data was obtained
per section 3.2.7. Endothermic peaks where Td was recorded are within the red circle.

4.7.

NEX as a Control for Formaldehyde Crosslinking

Formaldehyde is a well-known tissue fixative that is used widely throughout
laboratory practices. As discussed in section 1.6.1, formaldehyde is capable of forming
crosslinks with collagen molecules using available amine functionalities.

These

crosslinks may affect resistance to collagenase treatment as well as collagen thermal
stability. In order to determine these effects, the NEX group (section 3.2.2) was used as a
control for both collagenase and DSC experiments (sections 3.2.6 and 3.2.7).
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Results after collagenase treatment showed no significant difference in the
percentage of weight loss amongst any groups (Figure 4.16). Weight loss by the NEX
group was 13.02 + 1% while the NEN group lost 14.01 + 1.76% weight after collagenase.
This suggests that formaldehyde crosslinking had no affect on the enzymatic stability of
collagen. On the other hand, formaldehyde was found to have an effect on the degree of
crosslinking within the tissue.
This effect was characterized by measuring the average collagen denaturation
temperature using DSC (Figure 4.17). The NEX group was found to have a much lower
Td than the NEN group (p<0.001), measured at 87.225 + 0.45°C. This was 6.38 + 0.82
°C lower than the measured Td for the NEN group at 93.6 + 0.38 °C and suggests that
formaldehyde greatly increased the degree of crosslinking within cusp tissue. However,
the Td of NEN was not found to be significantly different from GLUT suggesting that the
NEN treatment without formalin (NEX) may provide a sufficient degree of crosslinking
for use in BHVs. A visual overview of this can also be seen through the similarities
between the DSC curves of GLUT and NEX displayed in Figure 4.15.

Figure 4.16: Results of collagenase digestion per section 3.2.6 expressed as % weight
loss. No significant differences were detected (p<0.05, n=6 per group).
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Figure 4.17: Collagen denaturation temperatures as measured by DSC (section 3.2.7).
“Red Star” signifies significant difference from NEN (p<0.05, n=4 per group).

4.8.

Rat Subdermal Study: GAG Preservation and Calcification

Rat subdermal implantation was performed to study calcification and in vivo
GAG stability. The amount of GAGs remaining in the tissues after explant was measured
by hexosamine assay and verified visually using histology. The NEN group exhibited the
highest GAG levels remaining within the tissue at 152.74 + 16.42 µg GAGs / 10 mg dry
tissue. This is similar to levels measured from in vitro studies after storage in buffer,
suggesting near full protection against GAG loss from in vivo degradation. This was
significantly higher than levels for both the EDC and GLUT groups, which measured
112.57 + 8.95 µg GAGs / 10 mg dry tissue and 97.64 + 6.50 µg GAGs / 10 mg dry tissue,
respectively. There was no significant difference detected between GAG amounts in the
EDC and GLUT tissues (p=0.20). The NEN group preserved 40.17 + 25.37 µg GAGs /
10 mg dry tissue more than the EDC group, which was found to be significant (p=0.045).
This suggests that the addition of neomycin into EDC/NHS crosslinked tissue provides
additional protection against GAG degradation from in vivo sources.
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Figure 4.18: Measure of GAGs remaining in the tissue after rat subdermal implantation
by hexosamine assay. “Red star” indicates significant difference from GLUT. “Green
Star” signifies significant differences from EDC. (p<0.05, n=10 per group).
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Figure 4.19: Histological sections of porcine aortic valve cusps after rat subdermal
implantation (Alcian blue staining, blue indicates the presence of GAGs). [A] GLUT
[B] EDC [C] NEN.

Visual review of histology sections largely corresponds with hexosamine assay
results, except that EDC is suggested to offer slight improvements on GAG retention.
Again, this may be due to brief storage in formalin prior to embedding and sectioning.
However, it is still very clear that NEN tissues retained a superior amount of GAGs as
indicated by intense blue staining, while GLUT exhibits very light blue staining.
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Rat subdermal implantation was also used to study the effects of the various
fixation methods on calcification. Calcium and phosphorus levels were measured after
tissues were explanted, as calcium and phosphate are key players in BHV mineralization
[5,6,78,79,147]. No significant differences were detected between any groups when
analyzed for calcium content. Calcium levels for the EDC and NEN groups were found
to be similar at 63.96 + 6.12 µg/mg dry tissue and 64.16 + 11.95 µg/mg dry tissue,
respectively. These values were both lower than the GLUT group at 83.60 + 6.12 µg/mg
dry tissue, but not significantly so, with p=0.115 when compared to EDC and p=0.199
when compared to NEN (Figure 4.20).
Measured phosphorus content in the cusps demonstrated an identical trend. There
were no significant differences observed between any of the groups although the EDC
and NEN groups appeared to be slightly lower than GLUT (Figure 4.20).

GLUT

phosphorus levels were measured as 41.2 + 2.61 µg/mg dry tissue, while EDC and NEN
groups seemed to be lower on average (p=0.06 and p=0.14, respectively).

EDC

phosphorus levels were measured as 29.9 + 4.52 µg/mg dry tissue and NEN was found to
be 30.4 + 5.89 µg/mg dry tissue.
The molar ratios of calcium to phosphorus were also calculated to further
characterize the tissue mineralization. The Ca:P molar ratios were similar for all groups
at 1.57, 1.65, and 1.63 for GLUT, EDC, and NEN groups, respectively. This suggests
similar progression of calcification for all groups and is indicative of hydroxyapatite
formation, which has a Ca:P molar ratio of 1.67. Despite the appearance of lower
mineralization in EDC and NEN, no differences found were significant. This suggests
that NEN treatment did not inhibit BHV cusp mineralization.
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Figure 4.20: Calcium and phosphorus content of cusp tissue after rat subdermal
implantation as measured using atomic absorption spectroscopy (section 3.2.12). No
significant differences were detected for any groups. (p<0.05, n=10 per group).

Histology was used to visually analyze the presence of calcification using Dahl’s
alizarin red stain (Figure 4.21). Observed tissue sections exhibited varying amounts of
calcification, as indicated by the presence of red staining. There appeared to be no
noticeable difference in the location of calcified areas, and the morphology of calcified
regions for all groups appeared to be very comparable to one another. This is expected as
the modes of mineralization where suggested to be the same, with hydroxyapatite
formation indicated for all groups. Visual analysis of all tissue section supports the
hypothesis that mineralization for all groups progressed similarly.
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Figure 4.21: Histological sections of porcine aortic valve cusps after rat subdermal
implantation (Dahl’s alizarin red staining, red indicates the presence of calcification).
[A] GLUT [B] EDC [C] NEN [D] GLUT [E] EDC [F] NEN.

4.9.

Characterization of Tissue Mechanics: Uniaxial Tensile Testing
4.9.1.

Stiffness (Modulus of Elasticity)

Modulus of elasticity (E) was used as a measure for tissue stiffness. Uniaxial
tensile testing was performed on all groups and the slope of the resulting stress-strain
curve was utilized to assess tissue stiffness. NEN was compared to GLUT and untreated
tissue (FRESH) for baseline controls. NEN was also compared to EDC to determine the
effects of neomycin and, likewise, was evaluated against NEX to ascertain the effects of
formaldehyde crosslinks. Stiffness was tested in both the radial and circumferential
directions, and both the low-end and high-end stiffness responses were recorded
(Figure 22 and Figure 23).
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The stiffness of GLUT tissue was significantly higher than FRESH on all
accounts, as expected (p<0.025). Also, stiffness in the circumferential direction was
found to be much higher than in the radial direction for every treatment group. The
stiffness of NEN tissue was found to be statistically higher than FRESH on all accounts
(p<0.001), except for the high-end response of the radial direction, which appeared to be
a very close approximation to the E of FRESH tissue (p=0.505). Stiffness for GLUT was
found to be significantly higher than NEN for the high-end response in both the radial
and circumferential direction (p<0.026). High-response E values for the NEN group
were 49.59 + 11.93% lower than GLUT in the circumferential direction and 30.91 +
9.53% lower in the radial direction. On the other hand, for the low-end response, no
significant difference was detected between NEN and GLUT groups for either direction.
Neomycin was only found to have a significant effect on stiffness for the low-end
response in the circumferential direction. In this one case, E for EDC was measured to
be 32.88 + 11.58% lower than NEN (p=0.044). This is at odds with results for all other
responses, where a trend seemed to form in which NEN stiffness appeared to be slightly
lower than EDC, although not significantly so. Formaldehyde only seemed to play a role
in stiffness for the low-end response, as no significant differences were found between
NEN and NEX for the high-end E values. Low-end response E values for NEX were
found to be significantly lower than NEN for both directions (p<0.048). E for NEX was
measured to be 56.07 + 10.91% lower in the circumferential direction and 28.28 +
10.23% lower in the radial direction. Overall, GLUT tissues appeared to be the stiffest
while FRESH tissues were, by far, the least stiff. Stiffness for NEN tissue seemed on the
middle ground, lower than or equal to GLUT and higher than or equal to FRESH.
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A

B

Figure 4.22: Modulus of Elasticity for porcine aortic valve cusps for the circumferential
direction.

[A] High-end response.

[B] Low-end response.

“Red Star” indicates

significant difference from GLUT. “Green Star” indicated significant difference from
FRESH (p<0.05, n=6 per group).
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A

B

Figure 4.23: Modulus of Elasticity for porcine aortic valve cusps for the radial direction.
[A] High-end response.
difference from GLUT.

[B] Low-end response.

“Red Star” indicates significant

“Green Star” indicated significant difference from FRESH

(p<0.05, n=6 per group).
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4.9.2.

Extensibility

For this study, extensibility is defined as the amount of strain the tissue allows
before transition to the collagen dominated high-end stiffness response. Uniaxial tensile
testing was performed on all groups, and the results from the stress-strain curve were
extrapolated to find extensibility. The slope line used to determine the high-end modulus
of elasticity was extended down to the x-axis, and the strain at this point was recorded as
the transition point, or extensibility (Figure 4.24).
Extensibility in the radial direction was much higher, overall, than in the
circumferential direction (Figure 4.25). This is expected as the tissue in the aortic valve
cusp has adapted to be much more yielding in the radial direction to aid in proper
function.

Extensibility of the tissue seemed to decrease after GLUT fixation, with

average GLUT extensibility values measuring 12.08 + 10.4% less than FRESH in the
radial direction and 16.31 + 3.17% less in the circumferential direction. However, only
the difference in the circumferential direction was found to be significant (p<0.001).
None of the EDC/NHS crosslinked groups were found to have any statistically
significant change in circumferential extensibility when compared to FRESH tissue
(p>0.12). All EDC/NHS crosslinked groups experienced increases in extensibility in the
radial direction, although EDC was not found to be statistically different from FRESH
(p=0.083). Extensibility for NEN was measured to be 27.62 + 13.98% higher than
FRESH (p=0.020) in the radial direction and 39.7 + 7.36% higher than GLUT (p<0.001).
Formaldehyde crosslinking appears to play no role in these measured extensibilities, as
no statistically significant differences in extensibility were found in either direction
between NEX and NEN.
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Figure 4.24: Stress-strain curve for GLUT tissue in the radial direction. The point at
which the thin red line crosses the x-axis was recorded as the strain for extensibility.

Figure 4.25: Extensibility for various groups in both the radial and circumferential
direction.

“Red Star” indicates significant difference from GLUT.

indicates significant difference from FRESH. (p<0.05, n=6 per group)
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“Green Star”

4.9.3.

Stress-Strain Relationship Observations

During stiffness and extensibility analysis, a unique attribute of certain stressstrain curves was noticed that distinguishes the different groups from one another. As
mentioned previously in section 1.5.3, the stress-strain relationship for heart valve cusp
tissue is highly non-linear and clearly separated into two regions. This was also verified
firsthand during uniaxial tensile testing on FRESH and GLUT tissue, where both groups
were found to express this relationship exactly (Figure 26A). However, all other groups
were found to demonstrate an additional third region (Figure 26B and 26C).
The third region appeared at the transition between the low-end response and the
high end-response, but only in the radial direction. Instead of the normal bend during
transition that is seen in GLUT and FRESH stress-strain curves, a clear “hump” is seen in
the stress-strain curve for all EDC/NHS crosslinked groups in the radial direction. This
hump is noticeable in the EDC group, but is much more pronounced in the NEN and
NEX groups. This suggests that not only does EDC/NHS crosslinking play a role in this
unique response, but neomycin does as well.

A

B

C

Figure 4.26: Comparing a normal two-region stress-strain curve two those with a thirdregion (This region is circled in red). [A] FRESH [B] EDC [C] NEN.
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5.

DISCUSSION

Calcification and non-calcific tissue damage are the two primary causes of
structural deterioration that lead to clinical BHV failure [5,76]. Collagen, elastin, and
remnant cell debris within BHV tissue are all recognized nucleation sites for calcification
[5,12]. Elastin calcification is thought to occur regardless of chemical modification [12];
however, there is evidence that mineralization at other sites is potentiated by
glutaraldehyde treatment [137,138]. Calcification is also exacerbated at sites of increased
mechanical stress, which highlights another major contributor to BHV failure,
mechanically induced tissue damage [124,127].
Non-calcific structural damage has been shown to occur independently of
calcification and roughly 90% of porcine aortic valve BHVs fail from structural damage
while showing little to no signs of calcification [76,81]. Degeneration in cyclic fatigue
testing suggests that mechanical stresses are a major source of non-calcific tissue damage
[124]. This may be due in part to glutaraldehyde fixation, which increases stiffness,
reduces extensibility, and fails to preserve GAGs within cusp tissue.
GAG loss has been connected to both tissue buckling and delamination and has
been documented in failed BHVs [19,31,77].

Even minor deviations from normal

biomechanics or tissue stress levels can lead to premature BHV dysfunction since
damage progresses unrestrained without the ability for BHV tissues to repair. This is
substantiated by cases of BHV failures that occurred as a result of only minor design
changes [139].

Therefore, the loss of GAGs in BHVs may indirectly lead to the

accumulation of collagen damage over time, ultimately contributing to BHV failure.
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5.1.

GAGs in BHVs

GAGs in BHV cusp tissue are primarily associated with the PGs versican and
decorin [19,131]. The functions of decorin are not fully understood, but have been
proposed to include roles in collagen fibril formation and organization as well as roles in
elastogenesis [140,141]. These functions cater to viable tissues, and the loss of these
GAGs may not significantly impact BHVs durability. Versican aids in tissue hydration,
helps control internal shear stress levels, absorb compressive loads, and promotes
smoother bending which helps prevent tissue buckling [31,140]. Versican also contains
elastin binding regions that may deter elastin calcification. This further establishes the
case that GAGs associated with versican play a much larger role in BHV durability [19].

5.2.

GAG Loss and Consequences

GAGs associated with decorin are more likely to be preserved by glutaraldehyde
due to a relatively unblocked protein core that is available for crosslinking. On the other
hand, GAGs related to versican are thought to remain unbound since the numerous
attached GAG chains hinder reaction by protein core with crosslinkers. Flourophoreassisted carbohydrate electrophoresis performed on clinical BHVs that failed due to
structural deterioration helped confirm these hypothesis [19]. Highly reduced levels of
chondroitin-6-sulfate were expressed, a GAG normally associated with versican [19].
Conversely, a high proportion of remaining GAGs were found to be chondroitin-4sulfate, which is commonly associated with decorin [19]. This is consistent with the
theory that GAG loss facilitates BHV failure, since versican loss would be much more
detrimental than decorin loss.
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Versican expression is highest in the spongiosa, and GAG loss associated with
versican leads to thinning of this tissue layer, a phenomenon observed in failed, explanted
BHVs [19,131]. The spongiosa is responsible for providing lubrication that reduces shear
stresses formed between the fibrosa and ventricularis that could otherwise lead to
delamination. Cyclic flexural fatigue demonstrated that delamination of the tissue layers
was the primary cause of BHV failure beginning at 10 million cycles [77]. Taken
together with another study that demonstrated that the majority of GAGs are loss in
glutaraldehyde fixed tissues by 10 million cycles, this advocates the role of GAGs in
preventing failure from delamination [15]. The onset of GAG loss at 10 million cycles is
also prior to collagen structural damage, which makes GAG loss a possible contributor to
structural deterioration [15]. GAG depleted tissues have also demonstrated greater tissue
buckling depth as well as increased flexural rigidity, both undesirable traits [18,31]. This
further demonstrates the importance of GAGs in BHV tissue, and again implicates
versican as a major source of GAG loss.
GAGs are not only lost during implantation and fatigue, but are also lost during
preparation and storage [31,75]. Loss can occur from the liberation of unbound GAGs,
but is also driven by enzymatic degradation since glutaraldehyde does not fully inactivate
GAG-degrading enzymes [75,83,142]. In addition to biomechanical repercussions, GAG
loss has also been suggested to impact BHV durability in other ways. The bulky nature
of versican has been stated to offer protection from proteolytic degradation by steric
interference [136], however this has been disputed [18]. Moreover, GAG loss was shown
to stimulate calcification in the rat subdermal model [86], and conversely GAG binding
was demonstrated to hinder mineralization [88,133], but this also faces debate [18].
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5.3.

GAG Preservation

Various fixation methods have been used to chemically stabilize GAGs to
improve preservation during storage, fatigue, and implantation. The uses of EDC/NHS
and sodium metaperiodate have both demonstrated improved GAG stabilization when
compared to glutaraldehyde treated tissues [88,132].

However, they were also

established to be only partially effective at protecting GAGs from enzymatic degradation.
Considering the fact that GAG degrading enzymes infiltrate BHV tissues after
implantation [25], additional protection against enzymatic degradation is needed.
Neomycin was employed by our lab using various fixation strategies and offered
improved GAG stability in tissues that were subjected to enzymatic degradation
[133,UD*]. The NEG group (Neomycin + EDC/NHS + Glutaraldehyde) demonstrated
superior GAG preservation but excessive crosslinking sacrificed the compliancy of cusp
tissue, which was demonstrated by biaxial and uniaxial analyses [30,133,UD]. The NG
group (Neomycin + Glutaraldehyde) demonstrated better compliancy along with
improved GAG preservation, but still lost GAGs during storage as lack of covalent GAG
crosslinking led to loss by leaching. [UD]. NG and NEG were both also subject to
calcification in the rat subdermal model, presumably, due to the use of glutaraldehyde
[133,UD]. We proposed the use of formaldehyde instead of glutaraldehyde, would yield
tissues with better mechanical properties since formaldehyde storage has previously been
demonstrated to better maintain tissue compliance [143]. Additionally, formaldehyde
performs many of the beneficial functions of glutaraldehyde, but may produce tissues
with reduced tendency to calcify. Therefore, we proposed that the use of EDC/NHS
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fixation in combination with neomycin and formaldehyde would provide the desired
stability to ECM components without sacrificing tissue compliance.

5.4.

Resistance to Enzymatic GAG Digestion

Past fixation strategies, NEG and NG, have utilized a 1 mM concentration of
neomycin to effectively shield GAGs from in vitro enzymatic degradation [133,UD].
The optimal neomycin concentration for the NEN treatment was found to be 0.5 mM,
which is in close agreement with unpublished data for both NEG and NG fixation
methods. The NEN group demonstrated complete resistance to GAGase digestion noting
no difference in the amount of GAGs remaining in cusp tissue after GAGase treatment.
GAG preservation was confirmed by analyzing the GAG content of the solutions, as well
as through histology. These results are similar to those previously found using NEG
fixation suggesting that the use glutaraldehyde is unnecessary to provide neomycin and
GAG stability when used with EDC and NHS [133].
EDC/NHS crosslinking, without the addition of neomycin, offered some
protection against in vitro enzymatic degradation, although not as complete as NEN
fixation. Carboxyl groups on the hexuronic acid repeats of GAGs have been shown to be
the initiating site for enzymatic attack by GAGases, and are the same groups used by
EDC and NHS for crosslink formation in NEN treated tissues [144]. Blockage of these
sites was shown to prevent enzymatic hydrolysis of β-(1,4) glycosidic linkages, which are
present on both hyaluronan and chondroitin sulfate (Figure 3B) [144]. According to
enzyme supplier’s website (www.sigmaaldrich.com), both the hyaluronidase and
chondroitinase used for these studies are capable of initiating cleavage at β-(1,4)
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glycosidic linkages. Therefore, steric interferences caused by these crosslinks are likely
the cause of EDC treated tissue’s resistance against GAGase degradation. However,
protection against GAG loss is only partial due to incomplete blocking of the activation
site along with insufficient crosslinking to safeguard all associated carboxyl groups.
All neomycin containing groups, NEN, NEG, and NG, have demonstrated
protection against both chondroitinase and hyaluronidase [133,UD]. This is probably due
to the fact that both enzymes exhibit similar cleavage mechanisms. According to the
enzyme supplier’s website, as stated above, both enzymes are capable of hydrolyzing β(1,4) glycosidic linkages on hyaluronan and chondroitin sulfate (Figure 3B). Protection
against both hyaluronidase and chondroitinase is critical for the full preservation of
versican aggregates in the spongiosa since they contain large amounts of both CS and HA
[17,19,131]. These aggregates have been established as a significant source of GAG loss
[19] and are likely the most important GAG structures when concerning protection
against mechanical fatigue damage in BHVs [18,30,31].
Protection against the enzymatic degradation of GAGs that is offered by
neomycin carried over into an in vivo model with the NEN treated tissues demonstrating
full GAG preservation after rat subdermal implantation for 3 weeks. There appeared to
be no significant amount of GAGs lost during 3 weeks of implantation when compared to
baseline GAG content for undigested tissues. This mirrors results previously obtained for
the NEG group, which demonstrated similar GAG preservation after 3 weeks of rat
subdermal implantation [133].

Again, this suggests that the use of glutaraldehyde

treatment is unnecessary to provide neomycin and GAG stability for tissues crosslinked
using EDC and NHS.
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5.5.

Controls for Neomycin

The inhibitory effect of neomycin on GAG degrading enzymes has previously
been demonstrated by both NEG and NG fixation methods [30,UD]. In order to verify
that neomycin was responsible for inhibiting GAGase activity, the GAG preserving
characteristics of 2-deoxystreptamine dihydrobromide (DOS), a molecule with
comparable structure to neomycin, were evaluated. Tissues treated with DOS along with
EDC, NHS, and glutaraldehyde failed to demonstrate matching enzymatic protection
against GAG loss to that of the NEG group, and exhibited significant amounts of GAG
loss after GAGase treatment [30].
For this study, a triple concentration of 1,6-hexane diamine was used as a control
for neomycin instead of an equal concentration of DOS. Previously, 1-6-hexane diamine
has been used to enhance EDC/NHS crosslinking [117], and a triple concentration was
used in order to provide a control for the number of provided amine functionalities (HEX
fixation). HEX treated tissues failed to provide protection against enzyme-initiated GAG
loss equal to that of NEN, losing a significant amount of GAGs after GAGase treatment.
This further demonstrates the GAG preserving properties of neomycin, and rules out the
contribution of amine functionalities to the protection of BHV tissues against enzymatic
GAG degradation.

5.6.

GAG Preservation During Storage

BHVs may be stored for up to three years from the moment of sterilization, in a
clinical setting [145]. During storage for a period up to 5 years, progressive GAG loss
has been shown to occur in glutaraldehyde treated BHV tissues.
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The addition of

neomycin to glutaraldehyde was shown to slow the rate of GAG loss during storage, as
demonstrated by NG fixation for storage up to 400 days [UD]. This demonstrates the
importance of protection from enzyme-initiated GAG degradation during storage,
considering that enzymatic activity is not abolished by glutaraldehyde fixation
[75,83,142]. However, GAG loss was only slowed by neomycin, not prevented, and
GAGs were still lost due to leaching. The additional use of EDC/NHS crosslinking
further preserved GAGs, and NEG treated tissues demonstrated negligible GAG losses
after 1 year of storage [30].
NEN treated tissues demonstrated similar characteristics by showing complete
GAG preservation throughout storage periods spanning 2, 4, and 6 months. Resistance to
direct GAGase digestion for the NEN group was also retained after 2 months of storage,
suggesting that the protective properties of neomycin do not degrade during short-term
storage. The effects of further storage on the decay of neomycin’s functions were not
tested for the NEN group, but a previous study has demonstrated that it still provides total
protection from direct GAGase digestion after 1 year of storage [30].

5.7.

Collagen and Elastin Stability

Collagen is the most prominent protein in BHV tissue and collagen fibers are
recognized as the most important structures regarding the overall integrity of BHVs. The
most common cause of collagen fiber disruption is non-calcific damage, which can be
mechanically induced or initiated by enzymatic activity [76,81,83].

Collagen

crosslinking due to glutaraldehyde fixation helps protect against autolytic degradation
[5,6]. This may occur during storage and implantation, as active proteolytic enzymes
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have been noted in BHV tissues after glutaraldehyde fixation [83], and have also been
found to inhabit clinically explanted BHV tissues [146].
Resistance to collagenase digestion has previously been used as a measure of
collagen stability [30] and was also used to assess the viability of NEN treated tissues.
Tissues crosslinked using the NEN treatment were found to demonstrate similar collagen
stability to those crosslinked using glutaraldehyde.

Neomycin improved upon the

collagen stability of EDC/NHS crosslinked tissue, with the NEN group showing less
weight loss than the EDC group.

However, this is due to the addition of amine

functionalities into the tissue and not a function specific to neomycin since the use of 1,6hexane diamine yielded similar improvement. Two hypotheses are offered as the reason
for the enhanced collagen stability offered by neomycin and 1,6-hexane diamine addition:
•

The bridging effect offered by polyamine molecules yields enhanced collagen
crosslinking via the ability to form different length crosslinks instead of only the
zero-length bonds formed by EDC and NHS.

•

The addition of more amines into the tissue allows additional crosslinks to be
formed, which leads to higher stability.

More carboxyl groups are readily

available on collagen than amine groups [115], leaving the number of amine
groups on collagen as the limiting factor in the number of possible crosslinks.
Previous use of 1,6-hexane diamine along with suberic acid, EDC, and NHS has also
been demonstrated to provide tissues with similar collagenase resistance to that afforded
by glutaraldehyde [117].

However, this treatment was not equally compared to

EDC/NHS fixation alone and therefore, enhanced EDC/NHS crosslinking by 1,6-hexane
diamine could not be confirmed.
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Since formaldehyde reacts with free amine groups on collagen molecules, the
effect of formaldehyde crosslinking on collagen stability was also evaluated. Despite the
monofunctional nature of formaldehyde, formaldehyde crosslinks actually provide
greater resistance to collagenase than the bifunctional glutaraldehyde at a concentration
of 1% [148]. This is most likely because of deeper penetration into the layers of collagen
structure allowed by formaldehyde’s small size [148]. The NEX group, identical to the
NEN group with the omission of formaldehyde, was found to have similar collagen
stability to NEN treated tissues. This suggests that formaldehyde does not affect the
collagenase resistance of tissues crosslinked using EDC, NHS, and neomycin.
Formaldehyde crosslinks may have no effect because the majority of collagen amines
have already reacted with EDC and NHS during NEN fixation.

The deeper level

crosslinks that are afforded by formaldehyde may also be inaccessible to collagenase and
fail to contribute to enzymatic resistance.
Assessing the loss of elastin is also important as it may augment the onset of
collagen damage indirectly through changes to BHV tissue mechanics. The stability of
elastin was also measured using resistance to elastase digestion, as done previously [30].
Like with collagen stability, similar elastin stability by both NEN and GLUT groups was
observed and the elastin stability of EDC tissue was improved by the addition of
neomycin. However, in this case, the action appears to be exclusive to neomycin, as the
HEX group did not experience the same effect. The mechanism behind neomycin’s
protection against elastase digestion is unknown, but was also previously demonstrated in
NEG and NG crosslinked tissues [30,UD].
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5.8.

Collagen Denaturation Temperature

The collagen denaturation temperature (Td) of BHV tissues is an indirect
measurement of the degree of collagen crosslinking. The Td for all groups was measured
using differential scanning calorimetry, which was first described in 1995 [135]. The
measured Td for GLUT was found to be around 86 °C, which is very similar to previously
reported values [135]. The measured Td for NEN and EDC were statistically higher than
GLUT, but not statistically different from one another. This suggests that neomycin has
little effect on the thermal stability of collagen structures.
The large increase in Td for EDC and NEN tissues was found to be a result of the
contribution from formaldehyde crosslinking.

The small size of the formaldehyde

molecule allows deep penetration into collagen structures initiating crosslinks all the way
down at the pentafibril level [148]. The increased amount of crosslinking allowed by
formaldehyde causes tissues to display a higher Td.

This is consistent with previous

studies that demonstrated a higher Td for formaldehyde crosslinked tissue than
glutaraldehyde crosslinked tissue [148].
The effect of formaldehyde crosslinking was confirmed as the NEX group was
measured to have a much lower Td than the NEN group. The measured Td of NEX tissue
was consistent with previously measured values for EDC/NHS crosslinked tissue [135];
further supporting the fact that neomycin does not affect thermal stability. The Td for the
NEX group was not statistically different from that of GLUT tissue, suggesting that
EDC/NHS crosslinking with neomycin provides sufficient crosslinking without the use of
formaldehyde.
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5.9.

Calcification

Glutaraldehyde crosslinking has previously been implicated to render BHV
tissues more conducive to calcification [5,62,78], and alternative crosslinking strategies,
using EDC and NHS, have demonstrated improved resistance to calcification in the rat
subdermal model [116,117,119]. Despite this fact, the EDC and NEN tissue groups did
not display significantly reduced calcification when compared to the GLUT group. This
may be due to the use of formaldehyde, which is part of the same family of chemicals as
glutaraldehyde and reacts with amine groups in an identical manner. These crosslinks
may aggravate the calcification of BHV tissues in a similar manner to glutaraldehyde
contributing to the calcification of EDC and NEN tissues. There was also no observed
difference between NEN and EDC tissue groups suggesting that neomycin does not affect
the calcification of cusp tissue.

This is consistent with previous data, which

demonstrated that neomycin does not affect the calcification of EDC/NHS crosslinked
tissue when used with glutaraldehyde [133].
The calcium to phosphorus molar ratios observed for all tissue groups were
comparable to those found in explanted BHV tissue, suggesting similar progression of
mineralization in both models [147]. The observed Ca:P molar ratios for all groups were
also close approximations of the molar ratio for hydroxyapatite, which is a known player
in BHV calcification [78,79,147]. Similar progression of calcification was also viewed
using histology, which noted no obvious differences in the morphology of calcified
regions.

The observed ratio values were slightly lower than the known ratio for

hydroxyapatite and may indicate increased proportions of dicalcium phosphate dihydrate
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and octacalcium phosphate.

These are precursors to hydroxyapatite that have been

documented in calcified BHV tissues [147].
It has previously been hypothesized that GAGs may, in some way, function to
inhibit BHV calcification and various studies have provided evidence to support this
claim [75,86-88]. It has previously been demonstrated that the removal of GAGs leads to
heightened levels of calcification [86]. Likewise, various methods of covalent GAG
binding have reduced calcification [87,88]. NEN tissues were found to fully preserve
GAGs during rat subdermal implantation; however, no reduction in calcification was
observed. This again may be due to the role of formaldehyde crosslinks in EDC and
NEN tissue calcification. These crosslinks may exacerbate tissue calcification to such a
degree that any inhibitory effects offered by GAG preservation are negated.

5.10.

Tissue Biomechanics

Tissue stiffness and extensibility were analyzed using uniaxial tensile testing
since they may have direct implications on stress levels and the amount of shock loading
experienced by BHV cusp tissue. Stiffness increase in cusp tissue is undesirable and has
been correlated with increased mechanical damage and lower BHV lifespan. The initial
generation of BHVs used high-pressure fixation to achieve proper coaptation and
aesthetic appeal. These valves had excessively stiff cusps and suffered from far inferior
durability when compared to later models [71]. Dermal collagen stiffness has been found
to rise with age and has also been proposed to affect heart valve cusp tissue [13,148].
This may further provide a correlation between stiffness and failure as incidences of
native heart increase valve disease increase with age [5].
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Glutaraldehyde treatment is known to cause an undesirable stiffness increase and
GLUT tissues were found to display a significantly higher stiffness than FRESH on all
accounts [152]. NEN tissue was significantly less stiff than GLUT for both directions in
the high-end response region. The high-end response in the radial direction was a close
approximation of natural stiffness, which is promising since cusp tissue experiences the
greatest amount of deformation in the radial direction. On the other hand, cusp tissue
experiences the highest amount of tension in the circumferential direction so a reduction
of high-end stiffness in this direction may be equally beneficial. NEN tissues did not
experience the same excessive stiffness increase that was observed in NEG tissues [UD].
This is most likely due to storage in formaldehyde, which was previously shown to better
preserve tissue compliance than glutaraldehyde [143].
Decreasing extensibility may also be related to failure and, like increased
stiffness, has also been found to occur with age in native valves [13,149]. Decreased
extensibility is also a result of elastin damage, which has been hypothesized to be a
possible contributor to BHV failure [150]. Finally, decreased extensibility has also been
documented in failed BHV explants [19,151]. When compared to FRESH tissue, GLUT
tissues demonstrated a significant decrease in extensibility in the circumferential
direction as observed previously [152]. All groups that utilized EDC/NHS crosslinking
performed better by demonstrating significantly higher extensibility than GLUT in both
directions and higher than FRESH in the radial direction. Also, the circumferential
extensibility for all EDC/NHS crosslinked groups was measured to be no different than
FRESH.

This is consistent with previous data that also demonstrated EDC/NHS

crosslinked tissues were more extensible than untreated tissues [115].

123

The differences in the mechanical properties of EDC/NHS crosslinked tissue from
GLUT and FRESH tissues may be explained by a single phenomenon. Bond formation
during carbodiimide crosslinking may cause the tissue to shrink offering an explanation
for increased extensibility as well as reduced high-end stiffness. Tissue shrinkage after
fixation would cause the initial length measurement used in strain calculations to be
smaller. Therefore, if two samples of similar size, one sample that underwent shrinkage
and a one that did not, were measured for extensibility at a common final length, the
resulting strain and extensibility would be larger for the tissue that underwent shrinkage.
This may also provide an explanation of the reduction in high-end stiffness since tissue
shrinkage may also cause collagen molecules to crimp or fold. When tension reaches the
high-end response, collagen will not be fully unfolded resulting in a lower stiffness as
collagen straightens and becomes more taut. Altered stiffness response may also simply
be due to differences in ECM microarchitecture, caused by differing crosslinking
chemistries.
The third response region that was demonstrated on the stress-strain curve may be
due to the formation of collagen-GAG crosslinks. Evidence for these crosslinks was
given by GAG preservation data, and would be a cause for a unique strain response under
tension. Since GAGs have little resistance to tensile force, this would only be viewed
under low tissue loads. This would account for the appearance of this unique response in
the lower stiffnesses of the radial direction.
Since tissue dimensions were not studied before and after fixation, talk of tissue
shrinkage is all conjecture. The effects of observed extensibility and stiffness changes on
BHV tissue durability are also not known, and cyclic fatigue or full-scale implantation
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models would be needed to study this. The effect of strain rate was also not investigated
and stress-strain responses were only analyzed at an arbitrary strain rate for relative ease.
It has previously been demonstrated, however, that the use of differing strain rates up to
physiological values has no affect on the stress-strain behavior of valve leaflet tissue
during biaxial tensile testing [129]. The effect of the third-response region is unknown,
and further study on all mechanical responses from biaxial mechanical testing or flexural
testing may be warranted. Lastly, the effects of GAG preservation by the NEN group on
tissue biomechanics have also not been elucidated and deserve further investigation.
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6.

CONCLUSIONS

The current average lifespan of implanted BHVs is inadequate in many cases,
causing contraindication of implantation, undesirable reoperation and even catastrophic
failure. Increasing BHV durability will not only improve the quality of life for BHV
recipients, but also open the door for more patients to become suitable candidates for
BHV replacement. In order to accomplish this, the foremost causes of BHV failure need
to be addressed.

It has been determined that structural dysfunction due to the

accumulation of collagen damage is the primary cause of BHV failure, with calcification
being a common co-contributor.

Current standard fixation methods, using

glutaraldehyde, may facilitate these modes of failure. Therefore, development of an
alternative fixation method may avoid the drawbacks of glutaraldehyde treatment,
yielding tissues with better properties that will increase the lifespan of BHVs.
Glycosaminoglycans are large, hydrated molecules that are present within the
specialized tissue layers of bioprosthetic heart valve tissue. The functions of these
molecules may be vital to preservation of proper tissue biomechanics and, consequently,
their loss may facilitate premature BHV failure. GLUT tissues were demonstrated to
experience GAG loss when subjected to enzymatic degradation, rat subdermal
implantation, and storage. EDC crosslinking enables the crosslinking of GAGs and
reduced losses due to enzymatic degradation and storage. However, protection against
GAG loss was incomplete and further protection against enzymatic degradation was
required. The use of neomycin in NEN treated tissues drastically improved resistance to
GAG loss, showing full preservation during enzymatic degradation, rat subdermal
implantation, and six months of storage.
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GAG preservation may be important, but preservation of collagen integrity is the
ultimate goal. Neomycin was also demonstrated to improve both the collagen and elastin
stability of carbodiimide crosslinked tissue. The NEN group displayed superior collagen
and elastin stability compared to EDC and was also a comparable match for GLUT. The
degree of crosslinking for NEN tissues was also found to be sufficient. The calcification
potential of NEN tissues was not determined to be significantly different from GLUT
tissues, and progression of tissue mineralization appeared to be identical for both groups.
This is thought to be due to the similar crosslinking mechanisms of formaldehyde and
glutaraldehyde.
On the other hand, analysis of biomechanics demonstrated clear differentiation in
responses between NEN and GLUT groups. GLUT tissues experienced an increase in
stiffness during fixation and were the stiffest tissues on average.

A reduction in

extensibility was also observed in the GLUT group. NEN tissues were measured to be
less stiff than GLUT on some accounts and were never found to be statistically stiffer.
NEN tissues also demonstrated vastly improved extensibility over GLUT tissues and
were even statistically higher than FRESH tissue in the radial direction.
We have demonstrated, that NEN tissues offer superior GAG preservation while
still providing the necessary stability for structural ECM components. NEN fixation was
not successful at reducing the calcification potential of cusp tissue, but yielded tissues
improved compliance and extensibility.

NEN fixation, and its associated GAG

preservation, may improve valve biomechanics and slow the onset of collagen damage.
As a result, the rate of structural degradation may be reduced resulting in improved
durability for BHV tissues.
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7.

FUTURE RECOMMENDATIONS

GAGs were demonstrated to be preserved using NEN fixation, but the effects of
their preservation were not investigated.

Analysis of valve biomechanics with and

without selective GAG removal could help reveal this. Any effects cause by longer
storage periods should also be studied as valves may be stored clinically for up to three
years. EDC and NHS utilize the carboxyl groups on GAGs to form the crosslinks that aid
in preservation. However, these same groups are necessary to retain the hydrophilic
properties of GAGs. Effects on tissue hydration should be studied along with any
associated changes this my cause to tissue biomechanics.
Since formaldehyde is suspected in the calcification experienced by the NEN
group, storage in an alternative reagent should be investigated. However, if formalin
storage is still determined to be favored, the use of anti-calcification treatments could also
be studied. Specific attention could also be paid to the areas in which calcification occur.
As GAGs have been associated with possible prevention of calcification, specific tissue
layers may be more resistant to calcification than others. Other segments of BHV tissue,
such as the aortic wall, should also be tested for calcification potential.
Further exploration into the mechanisms for the reduced stiffness and increased
extensibility is needed. Tissue dimensions should be measured before and after fixation
to determine the legitimacy of the tissue shrinkage hypothesis. Further research into the
effects of NEN fixation should also be performed including flexural testing, biaxial
tensile testing, and cyclic mechanical fatigue testing. Changes to valve biomechanics that
may occur during storage or fatigue should also be assessed. Lastly, these enhanced
biomechanical studies should also include studies into the effects of GAG preservation.
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